US20060217780A1 - Methods for treating essential tremor - Google Patents
Methods for treating essential tremor Download PDFInfo
- Publication number
- US20060217780A1 US20060217780A1 US11/249,034 US24903405A US2006217780A1 US 20060217780 A1 US20060217780 A1 US 20060217780A1 US 24903405 A US24903405 A US 24903405A US 2006217780 A1 US2006217780 A1 US 2006217780A1
- Authority
- US
- United States
- Prior art keywords
- patient
- information
- directing
- brain
- stimulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 114
- 201000006517 essential tremor Diseases 0.000 title claims abstract description 48
- 230000000638 stimulation Effects 0.000 claims abstract description 101
- 210000004556 brain Anatomy 0.000 claims abstract description 56
- 210000003205 muscle Anatomy 0.000 claims abstract description 49
- 230000001537 neural effect Effects 0.000 claims abstract description 38
- 230000009471 action Effects 0.000 claims abstract description 36
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000003925 brain function Effects 0.000 claims description 7
- 210000003625 skull Anatomy 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 abstract description 5
- 238000002595 magnetic resonance imaging Methods 0.000 abstract description 3
- 230000000007 visual effect Effects 0.000 abstract description 3
- 230000001144 postural effect Effects 0.000 abstract description 2
- 210000002569 neuron Anatomy 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 241001269524 Dura Species 0.000 description 10
- 206010044565 Tremor Diseases 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 208000016285 Movement disease Diseases 0.000 description 8
- 210000000337 motor cortex Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 6
- 210000003710 cerebral cortex Anatomy 0.000 description 6
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000002146 bilateral effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000011477 surgical intervention Methods 0.000 description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 3
- 230000036982 action potential Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 230000007177 brain activity Effects 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 229940090010 mysoline Drugs 0.000 description 3
- 229960002393 primidone Drugs 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 210000001103 thalamus Anatomy 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010073211 Postural tremor Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0531—Brain cortex electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36067—Movement disorders, e.g. tremor or Parkinson disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36135—Control systems using physiological parameters
Definitions
- the present invention is directed toward systems and methods for treating essential tremor, associated with abnormal neural activity in the brain.
- a wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain.
- various physical or cognitive functions are directed or affected by neural activity within the sensory or motor cortices.
- particular areas of the brain appear to have distinct functions.
- the areas of the occipital lobes relate to vision; the regions of the left interior frontal lobes relate to language; portions of the cerebral cortex appear to be consistently involved with conscious awareness, memory, and intellect; and particular regions of the cerebral cortex as well as the basal ganglia, the thalamus, and the motor cortex cooperatively interact to facilitate motor function control.
- Essential tremor is a frequently occurring, complex neurologic movement disorder. At this time, the causes of essential tremor are not well understood.
- Essential tremor typically affects the hands, but it can also affect the head and neck (causing shaking), the face, jaw, tongue, voice, trunk, and, on occasion, the legs and feet.
- the tremor can take the form of a rhythmic lateral motion or forward and aft motion produced by involuntary muscle contractions. The duration and intensity of the tremors can vary substantially from one day to the next and during the course of a given day.
- ET typically has two forms: postural tremor, which occurs when the patient holds the affected muscle in a particular position, and kinetic tremor, which occurs when the patient moves the affected muscle in a particular way. Most patients affected by ET have both postural and kinetic tremor symptoms.
- ET Effectively treating ET can be very difficult.
- Current treatments for ET symptoms include drugs, surgical intervention, and/or neural stimulation.
- Drug treatments or therapies may involve the administration of a beta-adrenergic blocker or anticonvulsant medication to the patient.
- Drug therapies may involve propanolol, mysoline, primidone, benzodiazepine, or a weak solution of botulinum toxin A.
- many patients cannot tolerate or fail to adequately respond to drug therapies.
- Surgical intervention for ET typically includes a thalamotomy, a procedure that involves ablating or destroying a selected portion of the thalamus.
- surgical intervention is a very time consuming and highly invasive procedure. Potential complications associated with the procedure include risk of hemorrhage, stroke, and/or paralysis.
- the procedures permanently destroy neural tissue, the effects of such intervention cannot be readily adjusted or “fine tuned” over time.
- Neural stimulation treatments have shown promising results for reducing some of the symptoms associated with ET.
- Neural activity is governed by electrical impulses or “action potentials” generated in and propagated by neurons. While in a quiescent state, a neuron is negatively polarized and exhibits a resting membrane potential that is typically between ⁇ 70 and ⁇ 60 mV.
- any given neuron receives excitatory and inhibitory input signals or stimuli from other neurons.
- a neuron integrates the excitatory and inhibitory input signals it receives, and generates or fires a series of action potentials in the event that the integration exceeds a threshold potential.
- a neural firing threshold for example, may be approximately ⁇ 55 mV. Action potentials propagate to the neuron's synapses and are then conveyed to other synaptically connected neurons.
- Neural activity in the brain can be influenced by neural stimulation, which involves the application of electrical and/or magnetic stimuli to one or more target neural populations within a patient using a waveform generator or other type of device.
- Various neural functions can thus be promoted or disrupted by applying an electrical current to one or more regions of the brain.
- researchers have attempted to treat certain neurological conditions, including ET, using electrical or magnetic stimulation signals to control or affect brain functions.
- Deep Brain Stimulation is a neural stimulation therapy that has been used as an alternative to drug treatments and ablative surgical therapies.
- DBS Deep Brain Stimulation
- one or more electrodes are surgically implanted into the brain proximate to deep brain or subcortical neural structures.
- an electrode is typically positioned in or proximate to the ventrointermediate nucleus (VIM) of the thalamus.
- VIM ventrointermediate nucleus
- a pulse generator delivers a continuous or essentially continuous electrical stimulation signal having a pulse repetition frequency of approximately 150 Hz to each of two deep brain electrodes.
- U.S. Pat. No. 5,883,709 discloses one conventional DBS system for treating movement disorders.
- DBS therapies may significantly reduce ET symptoms, particularly when combined with drug treatments, they are highly invasive procedures.
- configuring a DBS system to properly function within a patient requires a time consuming, highly invasive surgical procedure for implanting at least one, and possibly two, DBS electrodes.
- DBS surgical procedures have essentially the same risks as those described above for ablative surgical intervention.
- MCS Motor Cortex Stimulation
- ET and Parkinson's disease movement disorders
- MCS involves the application of stimulation signals to the motor cortex of a patient.
- One MCS system includes a pulse generator connected to a strip electrode that is surgically implanted over a portion of only the motor cortex (precentral gyrus).
- the use of MCS to treat symptoms associated with Parkinson's Disease is described in Canavero, Sergio, “ Extradural Motor Cortex Stimulation for Advanced Parkinson's Disease: Case Report, ” Movement Disorders (Vol. 15, No. 1, 2000).
- MCS involves the application of stimulation signals to surface regions of the brain rather than deep neural structures
- electrode implantation procedures for MCS are significantly less invasive and time consuming than those for DBS.
- MCS may be a safer and simpler alternative to DBS for treating ET symptoms.
- Present MCS techniques fail to address or adequately consider a variety of factors that may enhance or optimize the extent to which a patient experiences short term and/or long term relief from ET symptoms.
- FIGS. 1A-1B are flow charts illustrating methods for treating essential tremor in accordance with several embodiments of the invention.
- FIG. 2A is an image showing a mid saggital section of a brain of a patient.
- FIG. 2B is an image showing an axial view of a portion of the cerebral cortex of the brain of the patient.
- FIG. 3A is a side view of a brain of a patient with an electrode array implanted in accordance with one embodiment of the invention.
- FIG. 3B is a side view of a brain of a patient with an electrode array implanted in accordance with another embodiment of the invention.
- FIG. 4 is a side view of a brain of a patient showing one arrangement for applying neural stimulation to treat essential tremor.
- FIG. 5 is a cross-sectional view of the cerebral cortex of a patient illustrating an arrangement for treating essential tremor in accordance with another embodiment of the invention.
- FIG. 6 is a schematic view illustrating a system for treating essential tremor in accordance with still another embodiment of the invention.
- FIG. 7A-7B are flow charts illustrating methods for treating essential tremor in accordance with yet further embodiments of the invention.
- FIGS. 1A-7B Several features of methods and systems in accordance with embodiments of the invention are set forth and described in FIGS. 1A-7B . It will be appreciated that methods and systems in accordance with other embodiments of the invention can include additional procedures or features different than those shown in FIGS. 1A-78 . Additionally, methods and systems in accordance with several embodiments of the invention may not include all of the features shown in these Figures. Throughout the Figures, like reference numbers refer to similar or identical components or procedures.
- FIG. 1A is a flow chart illustrating a method for treating essential tremor in accordance with an embodiment of the invention.
- a method 100 a for treating essential tremor includes directing a patient to perform a muscle action (method portion 102 ).
- the muscle action can include maintaining the muscle in a certain position, and/or moving the muscle in a certain manner.
- the method 100 a can further include directing the collection of information corresponding to a level of neural activity in the patient's brain while the patient performs the muscle action (method portion 104 ).
- method portion 104 can be performed at least in part by a human operator, for example, a technician or doctor who operates an imaging system.
- the process of directing the collection of information can be performed partially or entirely by a computer, for example, by a hardware and/or software based routine that collects the information corresponding to the level of neural activity.
- the information can take several forms, and/or can correspond to the level of neural activity in the patient's brain by way of several techniques, as described in greater detail below with reference to FIG. 1B .
- the method 100 a includes at least reducing an essential tremor motion of the patient by applying an electrical stimulation at least proximate to a stimulation site, with the location of the stimulation site based at least in part on the information collected in method portion 104 .
- an operator and/or a computer-based set of instructions can apply an electrical stimulation to one or more electrodes or electrical contacts placed within the patient's brain. Further aspects of this and other embodiments of process portion 106 are also described in greater detail below with reference to FIG. 1B .
- FIG. 1B is a flow chart illustrating a method 100 b for treating essential tremor in accordance with another embodiment of the invention.
- the method 100 b includes further details of collecting information (method portion 104 , FIG. 1A ) and reducing essential tremor motion (method portion 106 , FIG. 1A ) associated with this embodiment.
- the method 100 b can include identifying a muscle action subject to essential tremor (method portion 110 ).
- a practitioner can direct the patient to perform a variety of movements, (e.g., for kinetic tremor) and/or assume a variety of positions (e.g., for postural tremor) while the practitioner observes the patient for an indication of essential tremor motion. Based on the results of this activity, the practitioner can single out one or more muscle actions that manifest essential tremor behavior or motion.
- the practitioner can monitor a first or baseline image of the patient's brain function while the patient is not performing the muscle action identified in method portion 110 (e.g., while the patient or relevant patient muscles are generally at rest, or the patient avoids performing the muscle action).
- the first image can be generated using functional magnetic resonance imaging (fMRI) techniques, magnetic resonance imaging (MRI) techniques, or computed tomography (CT) techniques.
- fMRI functional magnetic resonance imaging
- MRI magnetic resonance imaging
- CT computed tomography
- the first image can be generated by fMRI techniques that determine the level of the patient's brain function based on a measurement of blood oxygen levels in the patient's brain.
- the level of the patient's brain function is ascertained by other techniques.
- the first image can include an image of a portion of the patient's brain upon which is superimposed some indication of the brain activity level.
- the image can be color-coded to distinguish parts of the brain having a high level of activity (e.g., presented in one color) from portions of the brain having a relatively low level of activity (e.g., presented in another color).
- the image can include an image of the relative position between external markers and at least one of the central sulcus, precentral gyrus, and/or the postcentral gyrus of a patient.
- the external markers can be anatomical features of the patient (e.g., the patient's nose bridge or ear canal) or fiducials that are attached to the patient.
- the external markers can be fiducials that are attached to the skull of the patient.
- the practitioner can monitor a second image of the patient's brain function while the patient performs the muscle action identified in method portion 110 .
- the technique used to generate the second image is at least approximately identical to the technique used to produce the first image. Accordingly, the two images can be easily compared.
- the first and second images are compared to identify a stimulation site of the brain. For example, if a particular portion of the brain shows activity when the patient executes an essential tremor motion or assumes an essential tremor posture, this region can be identified by comparing the first image with the second image.
- a portion of the brain responsible for coordinating the muscle movement required to execute the motion or assume the posture may also be a portion of the brain responsible for generating the tremor motion itself.
- the correlation between the portions of the brain responsible for these two functions may be less clear. In these situations, the practitioner may use additional techniques (described in greater detail below with reference to FIGS. 7A-7B ) to isolate the site responsible for tremor motion.
- the stimulation site can be generally proximate to the dura of the patient and can be positioned over at least the precentral gyrus of the cortex. In particular embodiments, the stimulation site can also be located over the central sulcus and/or the postcentral gyrus of the patient. In any of these embodiments, the methods 100 a and 100 b result in an accurate determination of the location of the underlying cortical features relative to external landmarks on the patient. As explained in more detail below, this is expected to significantly improve the efficacy of stimulation therapies for treating ET.
- the practitioner can place at least one electrode at least proximate to the stimulation site determined in method portion 116 .
- the patient's essential tremor motion is reduced or eliminated by applying an electrical stimulation at least proximate to the stimulation site.
- the neural stimulation can be an electrical current applied epidurally or subdurally to the stimulation site.
- the method 100 b can include implanting an electrode at least proximate to the dura at the stimulation site.
- the neural stimulation can be transcutaneous magnetic stimulation.
- FIGS. 2A and 2B are examples of images corresponding to method portions 104 , 112 and 114 ( FIG. 1B ).
- FIG. 2A is a magnetic resonance image 200 a showing a view of the brain 210 of a patient P taken along a mid saggital section.
- the image 200 a shows the location of various features of the cerebral cortex 220 relative to fiducial markers 230 attached to the skull of the patient P.
- the pars marginalis sulcus 240 of the cortex 220 is located using the image 200 a of the mid saggital section. This particular image is useful because the pars marginalis sulcus is the only sulcus that can be followed into the interhemispheric fissure in this view.
- this position can be extrapolated to an axial image to determine the location of the central sulcus, the postcentral gyrus, and the precentral gyrus on the cortex 220 relative to the external markers.
- FIG. 2B is a magnetic resonance image 200 b of a brain of a patient taken along an axial section.
- the pars marginalis sulcus 240 appears as a small, symmetrical sulcus extending bilaterally out from the interhemispheric fissure.
- the position of the postcentral sulcus 242 can be determined by moving laterally (i.e., outward) from the pars marginalis sulcus 240 .
- the postcentral sulcus 242 forms the posterior boundary of the postcentral gyrus 260 , and thus the central sulcus 244 can be identified as the anterior boundary of the postcentral gyrus 260 .
- the central sulcus 244 forms the posterior boundary of the precentral gyrus 250 and the precentral sulcus 246 forms the anterior boundary of the precentral gyrus 250 .
- Identifying a stimulation site of the brain can also include identifying an external region on the patient relative to the location of the central sulcus 244 . After identifying the location of the central sulcus 244 on the image 200 b, the location of the central sulcus 244 is noted relative to the external markers 230 . Using standard neuronavigational MRI techniques, the data from the images can be transferred into an intraoperative navigational station that locates the external position on the scalp of the patient overlying the central sulcus 244 relative to the position of the fiducial markers 230 . The external position accordingly defines the general area where stimulation will be applied. The actual stimulation site is generally under the scalp at an area that is proximate to the dura of the patient and aligned with the external position identified on the patient.
- FIGS. 2A-2B refer to specific process portions (e.g., process portion 112 and 114 ) described above with reference to FIG. 1B that include monitoring images of the patient's brain.
- the method portion of directing the collection of information corresponding to a level of neural activity in the patient's brain while the patient performs a muscle action can be completed without generating an image.
- fMRI, MRI, or CT techniques can be used to generate a digital representation of brain activity without necessarily generating a visible image.
- an algorithm or other computer-based method can be used to determine the stimulation site, based upon the digital representation described above.
- the patient can receive electrical stimulation at the stimulation site via implanted electrodes. Techniques for placing the electrodes at the stimulation site are described in greater detail below with reference to FIGS. 3A-3C .
- FIGS. 3A-3B illustrate several embodiments of the process portion 118 ( FIG. 1B ) which includes placing at least one electrode at least proximate to a stimulation site.
- FIG. 3A is a schematic side view of the brain 200 illustrating a technique for implanting a linear electrode array 310 at a stimulation site 300 a proximate to the dura and over the precentral gyrus 250 , in accordance with an embodiment of the invention.
- the linear electrode array 310 has a plurality of electrodes 320 arranged along a single row. In other embodiments the linear electrode array 310 may have only one electrode 320 .
- the electrodes 320 can be circular contacts each having a surface area of approximately 5 mm 2 and being spaced apart by about 7.5 mm. In other embodiments, the electrodes can be other shapes and have other configurations, for example, those disclosed in pending U.S. application Ser. No. ______, entitled “Apparatuses and Systems for Applying Electrical Stimulation to a Patient,” (attorney docket no. 33734.8047US), filed ______ and incorporated herein by reference.
- the linear electrode array 310 has a lead 322 coupled to the electrodes 320 and an implanted pulse generator implanted above the neck or at a subclavicular location. The lead 322 is tunneled through the patient using standard techniques.
- the linear electrode array 310 can be positioned so that the row of electrodes 320 extends in a medial to lateral direction generally parallel with the central sulcus 244 .
- the electrodes 320 are also superimposed over the precentral gyrus 250 .
- the linear electrode array 310 generally has a plurality of electrodes 320 to provide extensive coverage over the precentral gyrus 250 and thus activate a large number of neurons in the motor cortex (e.g., use all of the electrodes) or only discrete populations of neurons in the motor cortex with only a single implantation of an electrode array (e.g., activate only selected electrodes).
- the electrode array 310 can be implanted so that the electrodes are proximate to the dura such as at an epidural or subdural location.
- FIG. 3B is a side-view of the brain 200 illustrating another embodiment for implanting an electrode array proximate to the dura at the stimulation site.
- the stimulation site 300 b is located over the precentral gyrus 250 and the postcentral gyrus 260 .
- a grid electrode array 330 is implanted at the stimulation site 300 b proximate to the dura.
- the grid electrode array 330 can include a plurality of first electrodes 340 a arranged along a first row and a plurality of second electrodes 340 b arranged along a second row.
- the first and second rows of electrodes 340 a - b can extend generally at an oblique angle relative to the central sulcus 244 .
- the grid electrode array 330 also has a lead 342 coupled to the electrodes 340 a - b and an implanted pulse generator. As with the linear electrode array 310 , the grid electrode array 330 can be implanted so that the electrodes are proximate to the dura.
- the stimulation sites 300 a and 300 b shown on FIGS. 3A and 3B may be located relative to the precentral gyrus 250 , the central sulcus 244 , and/or the postcentral gyrus 260 using the information collection and site selection procedures described above with reference to FIGS. 1A-2B .
- This enables the stimulation to be applied to desired locations on the cortex with much greater accuracy than previous methods that rely solely on the external anatomical features of the patient.
- the greater precision of locating the stimulation sites 300 a - b for implanting the electrode arrays is expected to enhance the efficacy of stimulation treatments for treating essential tremor.
- FIG. 4 is a side view illustrating several embodiments of applying neural stimulation directly to the stimulation site. More specifically, FIG. 4 illustrates the grid electrode array 330 positioned at the stimulation site 300 b over the precentral gyrus 250 , the central sulcus 244 , and the postcentral gyrus 260 .
- the neural stimulation can include passing an electrical current through the electrodes 340 a - b to the stimulation site 300 b. In one embodiment, the electrical current can be applied to a single one of the electrodes 340 a or 340 b to provide a monopolar pulse of current to a small area of the cortex 220 .
- a return electrode can be positioned elsewhere in the patient, such as on the other side of the patient's brain or at a subclavicular location.
- the return electrode can be a portion of a pulse generator or another electrode implanted elsewhere in the patient.
- electrical current can be passed through all of the electrodes 340 a - b or only a subset of these electrodes to activate larger or different populations of neurons.
- the potential applied to the electrodes 340 a - b can be the same across all of the activated electrodes to provide monopolar stimulation at the stimulation site.
- This embodiment also typically has a return electrode implanted elsewhere in the patient as explained above.
- some of the electrodes can be biased with a positive polarity and other electrodes can be biased with a negative polarity.
- the first electrodes 340 a can be biased with one polarity and the second electrodes 340 b can be biased with an opposite polarity.
- This embodiment provides a bipolar stimulation to the cortex 220 .
- the particular configuration of the electrodes can be optimized after implantation to provide the most efficacious therapy for the patient.
- the stimulus can have a waveform with a voltage of approximately 0.25 V-5.0 V, a pulse duration of approximately 20 microseconds-500 milliseconds, and a frequency of approximately 10 Hz-200 Hz.
- the electrical stimulus can have a voltage of 0.5 V-3.5 V, a pulse duration of 100 microseconds-200 microseconds, and a frequency of approximately 20 Hz-50 Hz.
- the voltage of the waveform can be approximately 2.0-3.5 V, and more particularly approximately around 3 V.
- the pulse duration can be in the range of 90-180 microseconds.
- the stimulus can be applied for a period of 0.5 hour-4.0 hours, and in many applications the therapy is applied for a period of approximately 0.5 hour-1.5 hours. In other embodiments, the stimulation can be applied continuously, or only during waking periods but not sleeping periods. Examples of specific stimulation protocols for use with an electrode array at an epidural stimulation site over the precentral gyrus are as follows:
- An electrical stimulus having a voltage of approximately 2.1 V, an impedance of 600 to 1000 Ohms, a pulse duration of 160 microseconds, and a frequency of approximately 130 Hz.
- the therapy is not applied continuously, but rather during 30-60 minute intervals.
- the stimulus has a voltage amplitude of approximately 3 V-3.5 V, a pulse duration of approximately 150-180 microseconds, and a frequency of approximately 25 Hz-31 Hz.
- the stimulus is applied continuously during waking periods, but it is discontinued during sleeping periods to conserve battery life of the implanted pulse generator.
- the stimulus has a voltage of approximately 3.0 V, a pulse duration of approximately 90 microseconds, and a frequency of approximately 30 Hz. This stimulus is applied continuously during waking and sleeping periods, but it can be discontinued during sleeping periods.
- FIG. 5 illustrates another aspect of an embodiment of the invention.
- the symptoms are manifested to a greater extent on one side of the body than the other.
- a patient may have a tremor in both hands, but usually one hand will have a tremor worse than the other hand.
- the patient's body is divided into a first side and a second side opposite the first side relative to a medial axis (e.g., right side-left side), and only one side of the cortex is stimulated to treat the disorder on both sides of the body.
- a medial axis e.g., right side-left side
- This embodiment can be carried out by implanting the electrode array 330 (or 310 ) at a stimulation site on only the first side of the patient when the disorder of a motor function is greater on the second side of the patient.
- the single electrode array can provide a bilateral affect that not only treats the disorder associated with the second side of the patient, but also treats the disorder associated with the first side of the patient. For example, if the patient experiences a bilateral tremor that is worse on the right side compared to the left side, then an electrode array can be implanted proximate to the dura over only the left hemisphere of the cortex 220 .
- the bilateral effect of the single-side stimulation may be enhanced using unipolar, monopolar, or isopolar stimulation techniques in which one or more nonfloating electrodes 320 are biased at an identical polarity.
- the bilateral effect may be caused by activation of commissural neurons (large pyramidal cells) in the deep portion of layer III of the motor cortex. Subsequent to activation, these neurons can depolarize complimentary cell groups in the contralateral hemisphere via the corpus callosum.
- commissural neurons large pyramidal cells
- these neurons can depolarize complimentary cell groups in the contralateral hemisphere via the corpus callosum.
- the single-side stimulation site may be particularly advantageous in certain situations because it requires only a single electrode array to be planted relative to a single hemisphere of the cortex 220 of the patient. This reduces the invasiveness and the risk associated with surgery.
- FIG. 6 is a schematic view illustrating a system for treating essential tremor in accordance with an embodiment of the invention.
- the system can include the linear electrode array 310 coupled to an implanted pulse generator 600 a implanted at a subclavicular location in the patient P.
- the grid electrode array 330 can be substituted for the linear electrode array 310 .
- a lead 322 / 342 is tunneled between the implanted pulse generator 600 a and the electrode array.
- the system has an implanted above-neck pulse generator 600 b that is smaller and configured to be implanted at a location above the neck of the patient P.
- the above-neck implanted pulse generator 600 b can be planted posteriorly of the ear of the patient P.
- the electrode arrays 310 or 330 are implanted underneath the skull S of the patient P at an epidural or subdural stimulation site as set forth above.
- FIGS. 7A-7B illustrate methods for treating essential tremor in accordance with further embodiments of the invention.
- a method 700 a includes directing a patient to perform an action with a first muscle on a first side of the patient's body, with the first muscle being controlled by a second hemisphere of the patient's brain (method portion 702 ).
- the action can include holding the muscle at a particular position or moving the muscle in a particular manner.
- the method further includes (while the patient performs the action with the first muscle) directing the collection of first information corresponding to a level of neural activity in the patient's brain (method portion 704 ).
- the patient is then directed to perform an action with a second muscle on a second side of the patient's body, the second muscle mirroring the first muscle and being controlled by the first hemisphere of the patient's brain (method portion 706 ).
- the method 700 a can include directing the collection of second information corresponding to a level of neural activity in the patient's brain (method portion 708 ).
- an essential tremor motion of the patient is reduced or eliminated by applying an electrical stimulation at least proximate to a stimulation site.
- the stimulation site is located based at least in part on a comparison of the first information with the second information.
- a practitioner can make use of the frequent tendency of the patient to manifest essential tremor symptoms on one side of the body more than on the other. For example, if the patient has more essential tremor motion associated with movement of the left hand than with the right hand, the practitioner can ask the patient to move the left hand and then view an image of the right side of the patient's brain while the patient undergoes the directed movement. The practitioner can then direct the patient to move the right hand while viewing an image of the left hemisphere of the patient's brain.
- the practitioner can attribute common aspects of the active areas of the images to brain activity associated with non-essential tremor movement, and differences between active areas of the images with motion related to essential tremor.
- the common aspects of the images can include common areas or volumes indicated to have heightened neural activity.
- the common aspects can include areas or volumes that have the same level of heightened neural activity.
- the practitioner can compare the two images to more accurately identify the portion of the brain associated with the essential tremor motion and can therefore more accurately target this portion of the brain with electrical stimulation.
- some or all of the foregoing method portions can be executed automatically by a computer and without generating a visual image.
- a method 700 b in accordance with another embodiment of the invention includes directing the collection of first information corresponding to a level of neural activity in the patient's brain while the patient performs a muscle action (method portion 720 ).
- the patient's motor nerves are affected by introducing a drug into the patient's body.
- the method 700 b further includes directing the collection of second information corresponding to a level of neural activity in the patient's brain while the patient performs the muscle action and while the patient is under the influence of the drug (method portion 724 ).
- the patient's essential tremor motion is at least reduced by applying an electrical stimulation at least proximate to a stimulation site, with a location of the stimulation site being based at least in part on a comparison of the first information with the second information.
- an electrical stimulation at least proximate to a stimulation site, with a location of the stimulation site being based at least in part on a comparison of the first information with the second information.
- alcohol or other drugs such as propanolol, mysoline, primidone, benzodiazepine or botulinum toxin A.
- a practitioner can compare neural information associated with muscle action before and after the influence of the drug to more readily determine the location of the patient's brain responsible for the essential tremor motion alone. Accordingly, the practitioner can more accurately target electrical stimulation to this location.
- the patient can receive drug therapy in conjunction with the electrical stimulation.
- the drug is administered to the patient so as to be active in the patient's system during electrical stimulation treatment.
- the drug can include alcohol, propanolol, mysoline, primidone, benzodiazepine or botulinum toxin A.
- the drug can have other constituents.
- the leads of the electrode arrays may be coupled to an external pulse generator instead of an implanted pulse generator.
- Methods and systems in accordance with other embodiments of the invention are included in pending U.S. Provisional Application No. 60/432,073, (attorney docket no. 33734.8040US) entitled “System and Method for Treating Parkinson's Disease and other Movement Disorders,” filed Dec. 9, 2002 and pending U.S. application Ser. No. 10/317,002 (attorney docket no.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Electrotherapy Devices (AREA)
Abstract
Methods for treating essential tremor are disclosed. A method in accordance with one embodiment of the invention includes directing a patient to perform a muscle action, for example, a postural or kinetic muscle action. The method can further include directing information to be collected, with the information corresponding to a level of neural activity in the patient's brain while the patient performs the muscle action. The essential tremor motion of the patient can then be at least reduced by applying an electrical stimulation at least proximate to a stimulation site, with the location of the stimulation site being based at least in part on the collected information. The information can include visual images, such as are generated by MRI, fMRI, or CT techniques, or the information can be non-visual. In particular embodiments, the location of the stimulation site can be determined by comparing two pieces of information, for example, neural activities before and after drug intake, or neural activities at the left and right hemispheres of the brain.
Description
- The present application claims priority to pending U.S. Provisional Application 60/432,073, entitled “System and Method for Treating Parkinson's Disease and other Movement Disorders,” filed December 9, 2002.
- The present invention is directed toward systems and methods for treating essential tremor, associated with abnormal neural activity in the brain.
- A wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain. For example, various physical or cognitive functions are directed or affected by neural activity within the sensory or motor cortices. Across most individuals, particular areas of the brain appear to have distinct functions. In the majority of people, for example, the areas of the occipital lobes relate to vision; the regions of the left interior frontal lobes relate to language; portions of the cerebral cortex appear to be consistently involved with conscious awareness, memory, and intellect; and particular regions of the cerebral cortex as well as the basal ganglia, the thalamus, and the motor cortex cooperatively interact to facilitate motor function control.
- Essential tremor is a frequently occurring, complex neurologic movement disorder. At this time, the causes of essential tremor are not well understood.
- Essential tremor (or ET) typically affects the hands, but it can also affect the head and neck (causing shaking), the face, jaw, tongue, voice, trunk, and, on occasion, the legs and feet. The tremor can take the form of a rhythmic lateral motion or forward and aft motion produced by involuntary muscle contractions. The duration and intensity of the tremors can vary substantially from one day to the next and during the course of a given day. ET typically has two forms: postural tremor, which occurs when the patient holds the affected muscle in a particular position, and kinetic tremor, which occurs when the patient moves the affected muscle in a particular way. Most patients affected by ET have both postural and kinetic tremor symptoms.
- Effectively treating ET can be very difficult. Current treatments for ET symptoms include drugs, surgical intervention, and/or neural stimulation. Drug treatments or therapies may involve the administration of a beta-adrenergic blocker or anticonvulsant medication to the patient. Drug therapies may involve propanolol, mysoline, primidone, benzodiazepine, or a weak solution of botulinum toxin A. Unfortunately, many patients cannot tolerate or fail to adequately respond to drug therapies.
- Surgical intervention for ET typically includes a thalamotomy, a procedure that involves ablating or destroying a selected portion of the thalamus. Unfortunately, surgical intervention is a very time consuming and highly invasive procedure. Potential complications associated with the procedure include risk of hemorrhage, stroke, and/or paralysis. Furthermore, because the procedures permanently destroy neural tissue, the effects of such intervention cannot be readily adjusted or “fine tuned” over time.
- Neural stimulation treatments have shown promising results for reducing some of the symptoms associated with ET. Neural activity is governed by electrical impulses or “action potentials” generated in and propagated by neurons. While in a quiescent state, a neuron is negatively polarized and exhibits a resting membrane potential that is typically between −70 and −60 mV. Through chemical connections known as synapses, any given neuron receives excitatory and inhibitory input signals or stimuli from other neurons. A neuron integrates the excitatory and inhibitory input signals it receives, and generates or fires a series of action potentials in the event that the integration exceeds a threshold potential. A neural firing threshold, for example, may be approximately −55 mV. Action potentials propagate to the neuron's synapses and are then conveyed to other synaptically connected neurons.
- Neural activity in the brain can be influenced by neural stimulation, which involves the application of electrical and/or magnetic stimuli to one or more target neural populations within a patient using a waveform generator or other type of device. Various neural functions can thus be promoted or disrupted by applying an electrical current to one or more regions of the brain. As a result, researchers have attempted to treat certain neurological conditions, including ET, using electrical or magnetic stimulation signals to control or affect brain functions.
- Deep Brain Stimulation (DBS) is a neural stimulation therapy that has been used as an alternative to drug treatments and ablative surgical therapies. In DBS, one or more electrodes are surgically implanted into the brain proximate to deep brain or subcortical neural structures. For treating ET, an electrode is typically positioned in or proximate to the ventrointermediate nucleus (VIM) of the thalamus. In a typical DBS system, a pulse generator delivers a continuous or essentially continuous electrical stimulation signal having a pulse repetition frequency of approximately 150 Hz to each of two deep brain electrodes. U.S. Pat. No. 5,883,709 discloses one conventional DBS system for treating movement disorders.
- Although DBS therapies may significantly reduce ET symptoms, particularly when combined with drug treatments, they are highly invasive procedures. In general, configuring a DBS system to properly function within a patient requires a time consuming, highly invasive surgical procedure for implanting at least one, and possibly two, DBS electrodes. DBS surgical procedures have essentially the same risks as those described above for ablative surgical intervention.
- Motor Cortex Stimulation (MCS) is another type of brain stimulation treatment that has been proposed for treating movement disorders, such as ET and Parkinson's disease. MCS involves the application of stimulation signals to the motor cortex of a patient. One MCS system includes a pulse generator connected to a strip electrode that is surgically implanted over a portion of only the motor cortex (precentral gyrus). The use of MCS to treat symptoms associated with Parkinson's Disease is described in Canavero, Sergio, “Extradural Motor Cortex Stimulation for Advanced Parkinson's Disease: Case Report,” Movement Disorders (Vol. 15, No. 1, 2000).
- Because MCS involves the application of stimulation signals to surface regions of the brain rather than deep neural structures, electrode implantation procedures for MCS are significantly less invasive and time consuming than those for DBS. As a result, MCS may be a safer and simpler alternative to DBS for treating ET symptoms. Present MCS techniques, however, fail to address or adequately consider a variety of factors that may enhance or optimize the extent to which a patient experiences short term and/or long term relief from ET symptoms.
-
FIGS. 1A-1B are flow charts illustrating methods for treating essential tremor in accordance with several embodiments of the invention. -
FIG. 2A is an image showing a mid saggital section of a brain of a patient. -
FIG. 2B is an image showing an axial view of a portion of the cerebral cortex of the brain of the patient. -
FIG. 3A is a side view of a brain of a patient with an electrode array implanted in accordance with one embodiment of the invention. -
FIG. 3B is a side view of a brain of a patient with an electrode array implanted in accordance with another embodiment of the invention. -
FIG. 4 is a side view of a brain of a patient showing one arrangement for applying neural stimulation to treat essential tremor. -
FIG. 5 is a cross-sectional view of the cerebral cortex of a patient illustrating an arrangement for treating essential tremor in accordance with another embodiment of the invention. -
FIG. 6 is a schematic view illustrating a system for treating essential tremor in accordance with still another embodiment of the invention. -
FIG. 7A-7B are flow charts illustrating methods for treating essential tremor in accordance with yet further embodiments of the invention. - The following disclosure describes several embodiments and systems for treating essential tremor and other movement disorders using cortical stimulation. Several features of methods and systems in accordance with embodiments of the invention are set forth and described in
FIGS. 1A-7B . It will be appreciated that methods and systems in accordance with other embodiments of the invention can include additional procedures or features different than those shown inFIGS. 1A-78 . Additionally, methods and systems in accordance with several embodiments of the invention may not include all of the features shown in these Figures. Throughout the Figures, like reference numbers refer to similar or identical components or procedures. -
FIG. 1A is a flow chart illustrating a method for treating essential tremor in accordance with an embodiment of the invention. In one embodiment, amethod 100 a for treating essential tremor includes directing a patient to perform a muscle action (method portion 102). The muscle action can include maintaining the muscle in a certain position, and/or moving the muscle in a certain manner. Themethod 100 a can further include directing the collection of information corresponding to a level of neural activity in the patient's brain while the patient performs the muscle action (method portion 104). In one aspect of this embodiment,method portion 104 can be performed at least in part by a human operator, for example, a technician or doctor who operates an imaging system. In another aspect of this embodiment, the process of directing the collection of information can be performed partially or entirely by a computer, for example, by a hardware and/or software based routine that collects the information corresponding to the level of neural activity. In either embodiment, the information can take several forms, and/or can correspond to the level of neural activity in the patient's brain by way of several techniques, as described in greater detail below with reference toFIG. 1B . - In
process portion 106, themethod 100 a includes at least reducing an essential tremor motion of the patient by applying an electrical stimulation at least proximate to a stimulation site, with the location of the stimulation site based at least in part on the information collected inmethod portion 104. For example, an operator and/or a computer-based set of instructions can apply an electrical stimulation to one or more electrodes or electrical contacts placed within the patient's brain. Further aspects of this and other embodiments ofprocess portion 106 are also described in greater detail below with reference toFIG. 1B . -
FIG. 1B is a flow chart illustrating amethod 100 b for treating essential tremor in accordance with another embodiment of the invention. Themethod 100 b includes further details of collecting information (method portion 104,FIG. 1A ) and reducing essential tremor motion (method portion 106,FIG. 1A ) associated with this embodiment. In one aspect of this embodiment, themethod 100 b can include identifying a muscle action subject to essential tremor (method portion 110). For example, a practitioner can direct the patient to perform a variety of movements, (e.g., for kinetic tremor) and/or assume a variety of positions (e.g., for postural tremor) while the practitioner observes the patient for an indication of essential tremor motion. Based on the results of this activity, the practitioner can single out one or more muscle actions that manifest essential tremor behavior or motion. - In
method portion 112, the practitioner can monitor a first or baseline image of the patient's brain function while the patient is not performing the muscle action identified in method portion 110 (e.g., while the patient or relevant patient muscles are generally at rest, or the patient avoids performing the muscle action). In one embodiment, the first image can be generated using functional magnetic resonance imaging (fMRI) techniques, magnetic resonance imaging (MRI) techniques, or computed tomography (CT) techniques. In a particular aspect of this embodiment, the first image can be generated by fMRI techniques that determine the level of the patient's brain function based on a measurement of blood oxygen levels in the patient's brain. In other embodiments, the level of the patient's brain function is ascertained by other techniques. In any of these embodiments, the first image can include an image of a portion of the patient's brain upon which is superimposed some indication of the brain activity level. For example, the image can be color-coded to distinguish parts of the brain having a high level of activity (e.g., presented in one color) from portions of the brain having a relatively low level of activity (e.g., presented in another color). The image can include an image of the relative position between external markers and at least one of the central sulcus, precentral gyrus, and/or the postcentral gyrus of a patient. The external markers can be anatomical features of the patient (e.g., the patient's nose bridge or ear canal) or fiducials that are attached to the patient. For example, the external markers can be fiducials that are attached to the skull of the patient. - In
method portion 114, the practitioner can monitor a second image of the patient's brain function while the patient performs the muscle action identified inmethod portion 110. In a particular aspect of this embodiment, the technique used to generate the second image is at least approximately identical to the technique used to produce the first image. Accordingly, the two images can be easily compared. - In
method portion 116, the first and second images are compared to identify a stimulation site of the brain. For example, if a particular portion of the brain shows activity when the patient executes an essential tremor motion or assumes an essential tremor posture, this region can be identified by comparing the first image with the second image. In some cases, a portion of the brain responsible for coordinating the muscle movement required to execute the motion or assume the posture may also be a portion of the brain responsible for generating the tremor motion itself. In other embodiments, the correlation between the portions of the brain responsible for these two functions may be less clear. In these situations, the practitioner may use additional techniques (described in greater detail below with reference toFIGS. 7A-7B ) to isolate the site responsible for tremor motion. In any of these embodiments, the stimulation site can be generally proximate to the dura of the patient and can be positioned over at least the precentral gyrus of the cortex. In particular embodiments, the stimulation site can also be located over the central sulcus and/or the postcentral gyrus of the patient. In any of these embodiments, themethods - In
method portion 118, the practitioner can place at least one electrode at least proximate to the stimulation site determined inmethod portion 116. Inmethod portion 120, the patient's essential tremor motion is reduced or eliminated by applying an electrical stimulation at least proximate to the stimulation site. The neural stimulation can be an electrical current applied epidurally or subdurally to the stimulation site. When the neural stimulation is an electrical current applied directly to the cerebral cortex proximate to the dura, themethod 100 b can include implanting an electrode at least proximate to the dura at the stimulation site. In other embodiments, the neural stimulation can be transcutaneous magnetic stimulation. Several aspects of electrodes, placement techniques, and stimulation techniques in accordance with particular embodiments of the invention are described in more detail below with respect toFIGS. 2A-7B . -
FIGS. 2A and 2B are examples of images corresponding tomethod portions FIG. 1B ).FIG. 2A is a magnetic resonance image 200 a showing a view of thebrain 210 of a patient P taken along a mid saggital section. The image 200 a shows the location of various features of thecerebral cortex 220 relative tofiducial markers 230 attached to the skull of the patient P. In one embodiment, the pars marginalissulcus 240 of thecortex 220 is located using the image 200 a of the mid saggital section. This particular image is useful because the pars marginalis sulcus is the only sulcus that can be followed into the interhemispheric fissure in this view. Based on the location of the pars marginalis sulcus shown in image 200 a, this position can be extrapolated to an axial image to determine the location of the central sulcus, the postcentral gyrus, and the precentral gyrus on thecortex 220 relative to the external markers. - In a further aspect of an embodiment of the
methods cortex 220 is generated.FIG. 2B is amagnetic resonance image 200 b of a brain of a patient taken along an axial section. Referring toFIG. 2B , the pars marginalissulcus 240 appears as a small, symmetrical sulcus extending bilaterally out from the interhemispheric fissure. Based upon the position of the pars marginalissulcus 240, the position of thepostcentral sulcus 242 can be determined by moving laterally (i.e., outward) from the pars marginalissulcus 240. Thepostcentral sulcus 242 forms the posterior boundary of thepostcentral gyrus 260, and thus thecentral sulcus 244 can be identified as the anterior boundary of thepostcentral gyrus 260. Similarly, thecentral sulcus 244 forms the posterior boundary of theprecentral gyrus 250 and theprecentral sulcus 246 forms the anterior boundary of theprecentral gyrus 250. - Identifying a stimulation site of the brain (
method portion 116,FIG. 1B ) can also include identifying an external region on the patient relative to the location of thecentral sulcus 244. After identifying the location of thecentral sulcus 244 on theimage 200 b, the location of thecentral sulcus 244 is noted relative to theexternal markers 230. Using standard neuronavigational MRI techniques, the data from the images can be transferred into an intraoperative navigational station that locates the external position on the scalp of the patient overlying thecentral sulcus 244 relative to the position of thefiducial markers 230. The external position accordingly defines the general area where stimulation will be applied. The actual stimulation site is generally under the scalp at an area that is proximate to the dura of the patient and aligned with the external position identified on the patient. -
FIGS. 2A-2B refer to specific process portions (e.g.,process portion 112 and 114) described above with reference toFIG. 1B that include monitoring images of the patient's brain. In other embodiments, the method portion of directing the collection of information corresponding to a level of neural activity in the patient's brain while the patient performs a muscle action (e.g.,method portion 104,FIG. 1A ) can be completed without generating an image. For example, fMRI, MRI, or CT techniques can be used to generate a digital representation of brain activity without necessarily generating a visible image. In a particular aspect of this embodiment, an algorithm or other computer-based method can be used to determine the stimulation site, based upon the digital representation described above. In either of these embodiments, the patient can receive electrical stimulation at the stimulation site via implanted electrodes. Techniques for placing the electrodes at the stimulation site are described in greater detail below with reference toFIGS. 3A-3C . -
FIGS. 3A-3B illustrate several embodiments of the process portion 118 (FIG. 1B ) which includes placing at least one electrode at least proximate to a stimulation site.FIG. 3A , more specifically, is a schematic side view of thebrain 200 illustrating a technique for implanting alinear electrode array 310 at astimulation site 300 a proximate to the dura and over theprecentral gyrus 250, in accordance with an embodiment of the invention. In one aspect of this embodiment, thelinear electrode array 310 has a plurality ofelectrodes 320 arranged along a single row. In other embodiments thelinear electrode array 310 may have only oneelectrode 320. Theelectrodes 320 can be circular contacts each having a surface area of approximately 5 mm2 and being spaced apart by about 7.5 mm. In other embodiments, the electrodes can be other shapes and have other configurations, for example, those disclosed in pending U.S. application Ser. No. ______, entitled “Apparatuses and Systems for Applying Electrical Stimulation to a Patient,” (attorney docket no. 33734.8047US), filed ______ and incorporated herein by reference. In one aspect of an embodiment shown inFIG. 3A , thelinear electrode array 310 has a lead 322 coupled to theelectrodes 320 and an implanted pulse generator implanted above the neck or at a subclavicular location. Thelead 322 is tunneled through the patient using standard techniques. - The
linear electrode array 310 can be positioned so that the row ofelectrodes 320 extends in a medial to lateral direction generally parallel with thecentral sulcus 244. Theelectrodes 320 are also superimposed over theprecentral gyrus 250. Thelinear electrode array 310 generally has a plurality ofelectrodes 320 to provide extensive coverage over theprecentral gyrus 250 and thus activate a large number of neurons in the motor cortex (e.g., use all of the electrodes) or only discrete populations of neurons in the motor cortex with only a single implantation of an electrode array (e.g., activate only selected electrodes). Theelectrode array 310 can be implanted so that the electrodes are proximate to the dura such as at an epidural or subdural location. -
FIG. 3B is a side-view of thebrain 200 illustrating another embodiment for implanting an electrode array proximate to the dura at the stimulation site. In this embodiment, thestimulation site 300 b is located over theprecentral gyrus 250 and thepostcentral gyrus 260. Agrid electrode array 330 is implanted at thestimulation site 300 b proximate to the dura. Thegrid electrode array 330 can include a plurality offirst electrodes 340 a arranged along a first row and a plurality ofsecond electrodes 340 b arranged along a second row. The first and second rows of electrodes 340 a-b can extend generally at an oblique angle relative to thecentral sulcus 244. Thegrid electrode array 330 also has a lead 342 coupled to the electrodes 340 a-b and an implanted pulse generator. As with thelinear electrode array 310, thegrid electrode array 330 can be implanted so that the electrodes are proximate to the dura. - One aspect of several embodiments of the invention is that the
stimulation sites FIGS. 3A and 3B may be located relative to theprecentral gyrus 250, thecentral sulcus 244, and/or thepostcentral gyrus 260 using the information collection and site selection procedures described above with reference toFIGS. 1A-2B . This enables the stimulation to be applied to desired locations on the cortex with much greater accuracy than previous methods that rely solely on the external anatomical features of the patient. The greater precision of locating the stimulation sites 300 a-b for implanting the electrode arrays is expected to enhance the efficacy of stimulation treatments for treating essential tremor. -
FIG. 4 is a side view illustrating several embodiments of applying neural stimulation directly to the stimulation site. More specifically,FIG. 4 illustrates thegrid electrode array 330 positioned at thestimulation site 300 b over theprecentral gyrus 250, thecentral sulcus 244, and thepostcentral gyrus 260. The neural stimulation can include passing an electrical current through the electrodes 340 a-b to thestimulation site 300 b. In one embodiment, the electrical current can be applied to a single one of theelectrodes cortex 220. A return electrode can be positioned elsewhere in the patient, such as on the other side of the patient's brain or at a subclavicular location. The return electrode can be a portion of a pulse generator or another electrode implanted elsewhere in the patient. In other embodiments, electrical current can be passed through all of the electrodes 340 a-b or only a subset of these electrodes to activate larger or different populations of neurons. In these embodiments, the potential applied to the electrodes 340 a-b can be the same across all of the activated electrodes to provide monopolar stimulation at the stimulation site. This embodiment also typically has a return electrode implanted elsewhere in the patient as explained above. In other embodiments, some of the electrodes can be biased with a positive polarity and other electrodes can be biased with a negative polarity. For example, thefirst electrodes 340 a can be biased with one polarity and thesecond electrodes 340 b can be biased with an opposite polarity. This embodiment provides a bipolar stimulation to thecortex 220. The particular configuration of the electrodes can be optimized after implantation to provide the most efficacious therapy for the patient. - The particular waveform of the stimuli depends upon the symptoms of the particular patients. In one embodiment, the stimulus can have a waveform with a voltage of approximately 0.25 V-5.0 V, a pulse duration of approximately 20 microseconds-500 milliseconds, and a frequency of approximately 10 Hz-200 Hz. In other embodiments, the electrical stimulus can have a voltage of 0.5 V-3.5 V, a pulse duration of 100 microseconds-200 microseconds, and a frequency of approximately 20 Hz-50 Hz. In still other embodiments, the voltage of the waveform can be approximately 2.0-3.5 V, and more particularly approximately around 3 V. Additionally, the pulse duration can be in the range of 90-180 microseconds. The stimulus can be applied for a period of 0.5 hour-4.0 hours, and in many applications the therapy is applied for a period of approximately 0.5 hour-1.5 hours. In other embodiments, the stimulation can be applied continuously, or only during waking periods but not sleeping periods. Examples of specific stimulation protocols for use with an electrode array at an epidural stimulation site over the precentral gyrus are as follows:
- An electrical stimulus having a voltage of approximately 2.1 V, an impedance of 600 to 1000 Ohms, a pulse duration of 160 microseconds, and a frequency of approximately 130 Hz. The therapy is not applied continuously, but rather during 30-60 minute intervals.
- The stimulus has a voltage amplitude of approximately 3 V-3.5 V, a pulse duration of approximately 150-180 microseconds, and a frequency of approximately 25 Hz-31 Hz. The stimulus is applied continuously during waking periods, but it is discontinued during sleeping periods to conserve battery life of the implanted pulse generator.
- The stimulus has a voltage of approximately 3.0 V, a pulse duration of approximately 90 microseconds, and a frequency of approximately 30 Hz. This stimulus is applied continuously during waking and sleeping periods, but it can be discontinued during sleeping periods.
-
FIG. 5 illustrates another aspect of an embodiment of the invention. In many cases of essential tremor, the symptoms are manifested to a greater extent on one side of the body than the other. For example, a patient may have a tremor in both hands, but usually one hand will have a tremor worse than the other hand. In this embodiment, the patient's body is divided into a first side and a second side opposite the first side relative to a medial axis (e.g., right side-left side), and only one side of the cortex is stimulated to treat the disorder on both sides of the body. This embodiment can be carried out by implanting the electrode array 330 (or 310) at a stimulation site on only the first side of the patient when the disorder of a motor function is greater on the second side of the patient. The single electrode array can provide a bilateral affect that not only treats the disorder associated with the second side of the patient, but also treats the disorder associated with the first side of the patient. For example, if the patient experiences a bilateral tremor that is worse on the right side compared to the left side, then an electrode array can be implanted proximate to the dura over only the left hemisphere of thecortex 220. The bilateral effect of the single-side stimulation may be enhanced using unipolar, monopolar, or isopolar stimulation techniques in which one or morenonfloating electrodes 320 are biased at an identical polarity. The bilateral effect may be caused by activation of commissural neurons (large pyramidal cells) in the deep portion of layer III of the motor cortex. Subsequent to activation, these neurons can depolarize complimentary cell groups in the contralateral hemisphere via the corpus callosum. By accurately locating the electrodes over the precentral gyrus using the information collection and site selection procedures described above, the electrode may maximally affect the contralateral lower extremity musculature and also the ipsilateral muscle groups. It is expected that the placement should be sufficiently remote from the interhemispheric fissure to avoid venous damage or occlusion. As a result, the single-side stimulation site may be particularly advantageous in certain situations because it requires only a single electrode array to be planted relative to a single hemisphere of thecortex 220 of the patient. This reduces the invasiveness and the risk associated with surgery. -
FIG. 6 is a schematic view illustrating a system for treating essential tremor in accordance with an embodiment of the invention. The system can include thelinear electrode array 310 coupled to an implantedpulse generator 600 a implanted at a subclavicular location in the patient P. Thegrid electrode array 330 can be substituted for thelinear electrode array 310. In either of these embodiments, alead 322/342 is tunneled between the implantedpulse generator 600 a and the electrode array. In another embodiment, the system has an implanted above-neck pulse generator 600 b that is smaller and configured to be implanted at a location above the neck of the patient P. The above-neck implantedpulse generator 600 b can be planted posteriorly of the ear of the patient P. In each of these embodiments, theelectrode arrays 310 or 330 (not shown inFIG. 6 ) are implanted underneath the skull S of the patient P at an epidural or subdural stimulation site as set forth above. -
FIGS. 7A-7B illustrate methods for treating essential tremor in accordance with further embodiments of the invention. Beginning withFIG. 7A , amethod 700 a includes directing a patient to perform an action with a first muscle on a first side of the patient's body, with the first muscle being controlled by a second hemisphere of the patient's brain (method portion 702). The action can include holding the muscle at a particular position or moving the muscle in a particular manner. The method further includes (while the patient performs the action with the first muscle) directing the collection of first information corresponding to a level of neural activity in the patient's brain (method portion 704). The patient is then directed to perform an action with a second muscle on a second side of the patient's body, the second muscle mirroring the first muscle and being controlled by the first hemisphere of the patient's brain (method portion 706). While the patient performs an action with the second muscle, themethod 700 a can include directing the collection of second information corresponding to a level of neural activity in the patient's brain (method portion 708). Inmethod portion 710, an essential tremor motion of the patient is reduced or eliminated by applying an electrical stimulation at least proximate to a stimulation site. The stimulation site is located based at least in part on a comparison of the first information with the second information. - In a particular aspect of an embodiment of the
method 700 a described above, a practitioner can make use of the frequent tendency of the patient to manifest essential tremor symptoms on one side of the body more than on the other. For example, if the patient has more essential tremor motion associated with movement of the left hand than with the right hand, the practitioner can ask the patient to move the left hand and then view an image of the right side of the patient's brain while the patient undergoes the directed movement. The practitioner can then direct the patient to move the right hand while viewing an image of the left hemisphere of the patient's brain. By comparing the two images, the practitioner can attribute common aspects of the active areas of the images to brain activity associated with non-essential tremor movement, and differences between active areas of the images with motion related to essential tremor. For example, in a particular embodiment, the common aspects of the images can include common areas or volumes indicated to have heightened neural activity. In other embodiments, the common aspects can include areas or volumes that have the same level of heightened neural activity. In either embodiment, the practitioner can compare the two images to more accurately identify the portion of the brain associated with the essential tremor motion and can therefore more accurately target this portion of the brain with electrical stimulation. In still further embodiments, (as described above), some or all of the foregoing method portions can be executed automatically by a computer and without generating a visual image. - Referring now to
FIG. 7B , amethod 700 b in accordance with another embodiment of the invention includes directing the collection of first information corresponding to a level of neural activity in the patient's brain while the patient performs a muscle action (method portion 720). Inmethod portion 722, the patient's motor nerves are affected by introducing a drug into the patient's body. Themethod 700 b further includes directing the collection of second information corresponding to a level of neural activity in the patient's brain while the patient performs the muscle action and while the patient is under the influence of the drug (method portion 724). Inmethod portion 726, the patient's essential tremor motion is at least reduced by applying an electrical stimulation at least proximate to a stimulation site, with a location of the stimulation site being based at least in part on a comparison of the first information with the second information. For example, it has been observed that a patient normally subject to essential tremor motion experiences a reduction in essential tremor motion when under the influence of alcohol or other drugs such as propanolol, mysoline, primidone, benzodiazepine or botulinum toxin A. A practitioner can compare neural information associated with muscle action before and after the influence of the drug to more readily determine the location of the patient's brain responsible for the essential tremor motion alone. Accordingly, the practitioner can more accurately target electrical stimulation to this location. - In any of the embodiments described above with reference to
FIGS. 1A-7B , the patient can receive drug therapy in conjunction with the electrical stimulation. For example, in a particular embodiment, the drug is administered to the patient so as to be active in the patient's system during electrical stimulation treatment. In a particular aspect of this embodiment, the drug can include alcohol, propanolol, mysoline, primidone, benzodiazepine or botulinum toxin A. In other embodiments, the drug can have other constituents. - From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. For example, the leads of the electrode arrays may be coupled to an external pulse generator instead of an implanted pulse generator. Methods and systems in accordance with other embodiments of the invention are included in pending U.S. Provisional Application No. 60/432,073, (attorney docket no. 33734.8040US) entitled “System and Method for Treating Parkinson's Disease and other Movement Disorders,” filed Dec. 9, 2002 and pending U.S. application Ser. No. 10/317,002 (attorney docket no. 33734.8048US), entitled “Systems and Methods for Enhancing or Optimizing Neural Stimulation Therapy for Treating Symptoms of Parkinson's Disease and/or Other Movement Disorders,” filed Dec. 10, 2002, both incorporated herein by reference. Accordingly, the invention is not limited except as by the appended claims.
Claims (20)
1. A method for treating essential tremor, comprising:
directing a patient to perform a muscle action;
directing information to be collected, the information corresponding to a level of neural activity in the patient's brain while the patient performs the muscle action; and
at least reducing an essential tremor motion of the patient by applying an electrical stimulation at least proximate to a stimulation site, the location of the stimulation site being based at least in part on the information.
2. The method of claim 1 wherein at least reducing an essential tremor motion includes eliminating the essential tremor motion.
3. The method of claim 1 wherein directing information to be collected includes directing a computer-based routine to collect the information.
4. The method of claim 1 , further comprising directing the formation of an image of at least a portion of the patient's brain, with at least a portion of the image having features representative of the information.
5. The method of claim 1 wherein directing information to be collected includes directing the formation an image of at least a portion of the patient's brain, the image including a first region with a characteristic of the first region having a first value, the image further including a second region with the characteristic of the second region having a second value different than the first value.
6. The method of claim 1 wherein directing information to be collected includes directing information to be collected on blood oxygen levels in the brain.
7. The method of claim, 1 further comprising locating the stimulation site relative to an anatomical feature of the patient.
8. The method of claim 1 further comprising locating the stimulation site relative to a fiducial having a fixed location relative to the patient's skull.
9. The method of claim 1 , further comprising implanting at least one electrode at least proximate to the stimulation site, and wherein applying an electrical stimulation includes applying an electrical signal to the at least one electrode.
10. The method of claim 1 wherein directing information to be collected while the patient performs a muscle action includes directing first information to be collected while the patient performs the muscle action a first time, and wherein the method further comprises:
affecting the patient's motor nerves by introducing a drug into the patient's body;
directing second information to be collected while the patient performs the muscle action a second time and while the patient is under the influence of the drug; and
directing a comparison of the first information with the second information to identify the stimulation site of the brain.
11. The method of claim 1 wherein at least reducing the patient's essential tremor further includes administering drugs to the patient.
12. The method of claim 1 wherein applying an electrical stimulation includes applying a varying electrical stimulation signal having a frequency of from about 5 Hz to about 200 Hz.
13. The method of claim 1 wherein applying an electrical stimulation includes applying a varying electrical stimulation signal having an electrical potential of from about 0.25 volts to about 5.0 volts.
14. The method of claim 1 wherein directing the patient to perform a muscle action includes directing the patient to move the muscle.
15. The method of claim 1 wherein directing the patient to perform a muscle action includes directing the patient to maintain a muscle in a particular position.
16. The method of claim 1 , further comprising placing an electrode at least proximate to the stimulation site.
17. The method of claim 1 wherein the information includes second information and applying an electrical stimulation at least proximate to a stimulation site includes applying an electrical stimulation to a stimulation site having a location based on a comparison of the second information with first information, the first information corresponding to a level of neural activity in the patient's brain while the patient does not perform the muscle action.
18. The method of claim 1 , further comprising:
directing the patient to undergo a plurality of muscle actions; and
selecting from the plurality of muscle actions a muscle action that produces a selected level of essential tremor motion, and wherein directing the patient to perform a muscle action includes directing the patient to perform the muscle action producing the selected level of essential tremor motion.
19. A method for treating essential tremor, comprising:
identifying a muscle action subject to essential tremor;
monitoring a first image of the patient's brain function while the patient is not performing the muscle action;
monitoring a second image of the patient's brain function while the patient performs the muscle action;
comparing the first and second images to identify a stimulation site of the brain;
placing at least one electrode at least proximate to the stimulation site;
at least reducing the patient's essential tremor motion by applying an electrical stimulation at least proximate to the stimulation site.
20-50. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/249,034 US20060217780A1 (en) | 2002-12-09 | 2005-10-11 | Methods for treating essential tremor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43207302P | 2002-12-09 | 2002-12-09 | |
US10/622,898 US6959215B2 (en) | 2002-12-09 | 2003-07-17 | Methods for treating essential tremor |
US11/249,034 US20060217780A1 (en) | 2002-12-09 | 2005-10-11 | Methods for treating essential tremor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/622,898 Continuation US6959215B2 (en) | 2002-12-09 | 2003-07-17 | Methods for treating essential tremor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060217780A1 true US20060217780A1 (en) | 2006-09-28 |
Family
ID=32474654
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/622,898 Expired - Fee Related US6959215B2 (en) | 2002-12-09 | 2003-07-17 | Methods for treating essential tremor |
US11/249,034 Abandoned US20060217780A1 (en) | 2002-12-09 | 2005-10-11 | Methods for treating essential tremor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/622,898 Expired - Fee Related US6959215B2 (en) | 2002-12-09 | 2003-07-17 | Methods for treating essential tremor |
Country Status (3)
Country | Link |
---|---|
US (2) | US6959215B2 (en) |
AU (1) | AU2003297762A1 (en) |
WO (1) | WO2004058347A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7869884B2 (en) | 2007-04-26 | 2011-01-11 | Cyberonics, Inc. | Non-surgical device and methods for trans-esophageal vagus nerve stimulation |
US7869867B2 (en) | 2006-10-27 | 2011-01-11 | Cyberonics, Inc. | Implantable neurostimulator with refractory stimulation |
US7869885B2 (en) | 2006-04-28 | 2011-01-11 | Cyberonics, Inc | Threshold optimization for tissue stimulation therapy |
US7904175B2 (en) | 2007-04-26 | 2011-03-08 | Cyberonics, Inc. | Trans-esophageal vagus nerve stimulation |
US7962220B2 (en) | 2006-04-28 | 2011-06-14 | Cyberonics, Inc. | Compensation reduction in tissue stimulation therapy |
US7962214B2 (en) | 2007-04-26 | 2011-06-14 | Cyberonics, Inc. | Non-surgical device and methods for trans-esophageal vagus nerve stimulation |
US7974701B2 (en) | 2007-04-27 | 2011-07-05 | Cyberonics, Inc. | Dosing limitation for an implantable medical device |
US7996079B2 (en) | 2006-01-24 | 2011-08-09 | Cyberonics, Inc. | Input response override for an implantable medical device |
US8150508B2 (en) | 2006-03-29 | 2012-04-03 | Catholic Healthcare West | Vagus nerve stimulation method |
US20120150257A1 (en) * | 2010-12-09 | 2012-06-14 | Dorian Aur | Seizure prediction and neurological disorder treatment |
US8204603B2 (en) | 2008-04-25 | 2012-06-19 | Cyberonics, Inc. | Blocking exogenous action potentials by an implantable medical device |
US8260426B2 (en) | 2008-01-25 | 2012-09-04 | Cyberonics, Inc. | Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device |
US8457747B2 (en) | 2008-10-20 | 2013-06-04 | Cyberonics, Inc. | Neurostimulation with signal duration determined by a cardiac cycle |
US8565867B2 (en) | 2005-01-28 | 2013-10-22 | Cyberonics, Inc. | Changeable electrode polarity stimulation by an implantable medical device |
US9314633B2 (en) | 2008-01-25 | 2016-04-19 | Cyberonics, Inc. | Contingent cardio-protection for epilepsy patients |
US9616234B2 (en) | 2002-05-03 | 2017-04-11 | Trustees Of Boston University | System and method for neuro-stimulation |
CN108211110A (en) * | 2013-01-21 | 2018-06-29 | 卡拉健康公司 | For controlling the device and method trembled |
US10653883B2 (en) | 2009-01-23 | 2020-05-19 | Livanova Usa, Inc. | Implantable medical device for providing chronic condition therapy and acute condition therapy using vagus nerve stimulation |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060217782A1 (en) * | 1998-10-26 | 2006-09-28 | Boveja Birinder R | Method and system for cortical stimulation to provide adjunct (ADD-ON) therapy for stroke, tinnitus and other medical disorders using implantable and external components |
US7062330B1 (en) * | 1998-10-26 | 2006-06-13 | Boveja Birinder R | Electrical stimulation adjunct (Add-ON) therapy for urinary incontinence and urological disorders using implanted lead stimulus-receiver and an external pulse generator |
US7831305B2 (en) | 2001-10-15 | 2010-11-09 | Advanced Neuromodulation Systems, Inc. | Neural stimulation system and method responsive to collateral neural activity |
US7236831B2 (en) * | 2000-07-13 | 2007-06-26 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7010351B2 (en) | 2000-07-13 | 2006-03-07 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7024247B2 (en) | 2001-10-15 | 2006-04-04 | Northstar Neuroscience, Inc. | Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures |
US7756584B2 (en) | 2000-07-13 | 2010-07-13 | Advanced Neuromodulation Systems, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7672730B2 (en) | 2001-03-08 | 2010-03-02 | Advanced Neuromodulation Systems, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7305268B2 (en) | 2000-07-13 | 2007-12-04 | Northstar Neurscience, Inc. | Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators |
US7221981B2 (en) | 2002-03-28 | 2007-05-22 | Northstar Neuroscience, Inc. | Electrode geometries for efficient neural stimulation |
US7236830B2 (en) | 2002-12-10 | 2007-06-26 | Northstar Neuroscience, Inc. | Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders |
US20050075680A1 (en) | 2003-04-18 | 2005-04-07 | Lowry David Warren | Methods and systems for intracranial neurostimulation and/or sensing |
US7565199B2 (en) * | 2002-12-09 | 2009-07-21 | Advanced Neuromodulation Systems, Inc. | Methods for treating and/or collecting information regarding neurological disorders, including language disorders |
JP2007501067A (en) | 2003-08-01 | 2007-01-25 | ノーススター ニューロサイエンス インコーポレイテッド | Apparatus and method for applying neural stimulation to patient |
US20050182456A1 (en) * | 2004-02-18 | 2005-08-18 | Ziobro John F. | Automated cortical mapping |
US20060004422A1 (en) * | 2004-03-11 | 2006-01-05 | Dirk De Ridder | Electrical stimulation system and method for stimulating tissue in the brain to treat a neurological condition |
US8337482B2 (en) | 2004-04-19 | 2012-12-25 | The Invention Science Fund I, Llc | System for perfusion management |
US9011329B2 (en) | 2004-04-19 | 2015-04-21 | Searete Llc | Lumenally-active device |
US8353896B2 (en) | 2004-04-19 | 2013-01-15 | The Invention Science Fund I, Llc | Controllable release nasal system |
US7998060B2 (en) | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling delivery device |
US8512219B2 (en) | 2004-04-19 | 2013-08-20 | The Invention Science Fund I, Llc | Bioelectromagnetic interface system |
US7857767B2 (en) | 2004-04-19 | 2010-12-28 | Invention Science Fund I, Llc | Lumen-traveling device |
US7850676B2 (en) | 2004-04-19 | 2010-12-14 | The Invention Science Fund I, Llc | System with a reservoir for perfusion management |
US8361013B2 (en) | 2004-04-19 | 2013-01-29 | The Invention Science Fund I, Llc | Telescoping perfusion management system |
US8019413B2 (en) | 2007-03-19 | 2011-09-13 | The Invention Science Fund I, Llc | Lumen-traveling biological interface device and method of use |
US8092549B2 (en) | 2004-09-24 | 2012-01-10 | The Invention Science Fund I, Llc | Ciliated stent-like-system |
EP1827569A4 (en) * | 2004-05-04 | 2008-04-16 | Cleveland Clinic Foundation | Corpus callosum neuromodulation assembly |
WO2005107854A2 (en) | 2004-05-04 | 2005-11-17 | The Cleveland Clinic Foundation | Corpus callosum neuromodulation assembly |
US7483747B2 (en) | 2004-07-15 | 2009-01-27 | Northstar Neuroscience, Inc. | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
US7565200B2 (en) | 2004-11-12 | 2009-07-21 | Advanced Neuromodulation Systems, Inc. | Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects |
US20060129056A1 (en) * | 2004-12-10 | 2006-06-15 | Washington University | Electrocorticography telemitter |
US8515541B1 (en) | 2004-12-22 | 2013-08-20 | Boston Scientific Neuromodulation Corporation | Methods and systems for treating post-stroke disorders |
US9307925B2 (en) | 2005-06-16 | 2016-04-12 | Aaken Laboratories | Methods and systems for generating electrical property maps of biological structures |
US7838526B2 (en) * | 2005-08-05 | 2010-11-23 | Esther Baldinger | Method of treating neurological disorders |
US7856264B2 (en) | 2005-10-19 | 2010-12-21 | Advanced Neuromodulation Systems, Inc. | Systems and methods for patient interactive neural stimulation and/or chemical substance delivery |
US7729773B2 (en) | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
US8929991B2 (en) | 2005-10-19 | 2015-01-06 | Advanced Neuromodulation Systems, Inc. | Methods for establishing parameters for neural stimulation, including via performance of working memory tasks, and associated kits |
US7774068B1 (en) | 2005-11-03 | 2010-08-10 | Lozano Andres M | System and method for treating movement disorders, including restless leg syndrome |
US7657310B2 (en) * | 2006-01-26 | 2010-02-02 | Cyberonics, Inc. | Treatment of reproductive endocrine disorders by vagus nerve stimulation |
US20120035540A1 (en) | 2006-04-12 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Event-based control of a lumen traveling device |
US8160680B2 (en) | 2006-04-12 | 2012-04-17 | The Invention Science Fund I, Llc | Autofluorescent imaging and target ablation |
US20080087288A1 (en) * | 2006-10-11 | 2008-04-17 | Kairos Systems, Inc. | Apparatus and methods for effecting therapy on a body |
BRPI0920821B8 (en) | 2008-10-01 | 2021-06-22 | Hua Sherwin | bone stabilization system and screw for use in bone stabilization |
US8255057B2 (en) * | 2009-01-29 | 2012-08-28 | Nevro Corporation | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
US20100274312A1 (en) | 2009-04-22 | 2010-10-28 | Konstantinos Alataris | Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods |
EP3228350A1 (en) | 2009-04-22 | 2017-10-11 | Nevro Corporation | Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods |
CN102791185A (en) | 2009-12-21 | 2012-11-21 | S·华 | Insertion of medical devices through non-orthogonal and orthogonal trajectories within the cranium and methods of using |
US8562523B2 (en) | 2011-03-04 | 2013-10-22 | Flint Hills Scientific, Llc | Detecting, assessing and managing extreme epileptic events |
US8684921B2 (en) | 2010-10-01 | 2014-04-01 | Flint Hills Scientific Llc | Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis |
US8562524B2 (en) | 2011-03-04 | 2013-10-22 | Flint Hills Scientific, Llc | Detecting, assessing and managing a risk of death in epilepsy |
US9504390B2 (en) | 2011-03-04 | 2016-11-29 | Globalfoundries Inc. | Detecting, assessing and managing a risk of death in epilepsy |
WO2013036880A1 (en) | 2011-09-08 | 2013-03-14 | Thacker James R | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
US10448839B2 (en) | 2012-04-23 | 2019-10-22 | Livanova Usa, Inc. | Methods, systems and apparatuses for detecting increased risk of sudden death |
US9056195B2 (en) | 2013-03-15 | 2015-06-16 | Cyberonics, Inc. | Optimization of cranial nerve stimulation to treat seizure disorderse during sleep |
ES2918799T3 (en) | 2013-05-08 | 2022-07-20 | Consejo Superior Investigacion | Neuroprosthetic device for the monitoring and suppression of pathological tremors through neurostimulation of afferent pathways |
US9895539B1 (en) | 2013-06-10 | 2018-02-20 | Nevro Corp. | Methods and systems for disease treatment using electrical stimulation |
US9302109B2 (en) | 2014-04-25 | 2016-04-05 | Cyberonics, Inc. | Cranial nerve stimulation to treat depression during sleep |
US9585611B2 (en) | 2014-04-25 | 2017-03-07 | Cyberonics, Inc. | Detecting seizures based on heartbeat data |
CN106413805A (en) | 2014-06-02 | 2017-02-15 | 卡拉健康公司 | Systems and methods for peripheral nerve stimulation to treat tremor |
AU2015301401B2 (en) | 2014-08-15 | 2020-01-16 | Axonics Modulation Technologies, Inc. | Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder |
JP6779860B2 (en) | 2014-08-15 | 2020-11-04 | アクソニクス モジュレーション テクノロジーズ インコーポレイテッド | Integrated EMG clinician programming device for use with implantable neurostimulators |
AU2015301400B2 (en) | 2014-08-15 | 2020-05-28 | Axonics Modulation Technologies, Inc. | Systems and methods for neurostimulation electrode configurations based on neural localization |
CA2988586A1 (en) | 2015-06-10 | 2016-12-15 | Cala Health, Inc. | Neuromodulation system for peripheral nerve stimulation with detachable therapy unit |
EP3352843B1 (en) | 2015-09-23 | 2021-06-23 | Cala Health, Inc. | Device for peripheral nerve stimulation in the finger to treat hand tremors |
JP6952699B2 (en) | 2016-01-21 | 2021-10-20 | カラ ヘルス, インコーポレイテッドCala Health, Inc. | Systems, methods and devices for peripheral nerve regulation to treat diseases associated with overactive bladder |
EP3481492B1 (en) | 2016-07-08 | 2024-03-13 | Cala Health, Inc. | Systems for stimulating n nerves with exactly n electrodes and improved dry electrodes |
US11331480B2 (en) | 2017-04-03 | 2022-05-17 | Cala Health, Inc. | Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder |
WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
EP3740274A4 (en) | 2018-01-17 | 2021-10-27 | Cala Health, Inc. | Systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11839583B1 (en) | 2018-09-11 | 2023-12-12 | Encora, Inc. | Apparatus and method for reduction of neurological movement disorder symptoms using wearable device |
US11701293B2 (en) | 2018-09-11 | 2023-07-18 | Encora, Inc. | Apparatus and method for reduction of neurological movement disorder symptoms using wearable device |
CA3112564A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US11160580B2 (en) | 2019-04-24 | 2021-11-02 | Spine23 Inc. | Systems and methods for pedicle screw stabilization of spinal vertebrae |
US11439829B2 (en) | 2019-05-24 | 2022-09-13 | Axonics, Inc. | Clinician programmer methods and systems for maintaining target operating temperatures |
US11848090B2 (en) | 2019-05-24 | 2023-12-19 | Axonics, Inc. | Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system |
US11890468B1 (en) | 2019-10-03 | 2024-02-06 | Cala Health, Inc. | Neurostimulation systems with event pattern detection and classification |
JP2024518177A (en) | 2021-05-12 | 2024-04-25 | スピン23 インコーポレイテッド | Systems and methods for pedicle screw stabilization of spinal vertebrae - Patents.com |
Citations (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3024702A (en) * | 1959-04-27 | 1962-03-13 | Reinholdt Friedrich | Emergency warning device |
US3650276A (en) * | 1969-03-26 | 1972-03-21 | Inst Demedicina Si Farmacie | Method and apparatus, including a flexible electrode, for the electric neurostimulation of the neurogenic bladder |
US4019518A (en) * | 1975-08-11 | 1977-04-26 | Medtronic, Inc. | Electrical stimulation system |
US4140133A (en) * | 1977-04-26 | 1979-02-20 | Moskovsky Oblastnoi Nauchno-Issledovatelsky Institut Akusherstva I Ginekolog Ii | Device for pulse current action on central nervous system |
US4245645A (en) * | 1977-09-28 | 1981-01-20 | Arseneault Pierre Michel | Self-locking cerebral electrical probe |
US4308868A (en) * | 1980-05-27 | 1982-01-05 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Implantable electrical device |
US4431000A (en) * | 1978-11-29 | 1984-02-14 | Gatron Corporation | Transcutaneous nerve stimulator with pseusorandom pulse generator |
US4646744A (en) * | 1984-06-29 | 1987-03-03 | Zion Foundation | Method and treatment with transcranially applied electrical signals |
US4817634A (en) * | 1987-06-18 | 1989-04-04 | Medtronic, Inc. | Epicardial patch electrode |
US4903702A (en) * | 1988-10-17 | 1990-02-27 | Ad-Tech Medical Instrument Corporation | Brain-contact for sensing epileptogenic foci with improved accuracy |
US5002053A (en) * | 1989-04-21 | 1991-03-26 | University Of Arkansas | Method of and device for inducing locomotion by electrical stimulation of the spinal cord |
US5092835A (en) * | 1990-07-06 | 1992-03-03 | Schurig Janet L S | Brain and nerve healing power apparatus and method |
US5184620A (en) * | 1991-12-26 | 1993-02-09 | Marquette Electronics, Inc. | Method of using a multiple electrode pad assembly |
US5193540A (en) * | 1991-12-18 | 1993-03-16 | Alfred E. Mann Foundation For Scientific Research | Structure and method of manufacture of an implantable microstimulator |
US5282468A (en) * | 1990-06-07 | 1994-02-01 | Medtronic, Inc. | Implantable neural electrode |
US5299569A (en) * | 1991-05-03 | 1994-04-05 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by nerve stimulation |
US5303705A (en) * | 1992-05-01 | 1994-04-19 | Nenov Valeriy I | Evoked 23NA MR imaging of sodium currents in the brain |
US5304206A (en) * | 1991-11-18 | 1994-04-19 | Cyberonics, Inc. | Activation techniques for implantable medical device |
US5405375A (en) * | 1994-01-21 | 1995-04-11 | Incontrol, Inc. | Combined mapping, pacing, and defibrillating catheter |
US5406957A (en) * | 1992-02-05 | 1995-04-18 | Tansey; Michael A. | Electroencephalic neurofeedback apparatus for training and tracking of cognitive states |
US5591216A (en) * | 1995-05-19 | 1997-01-07 | Medtronic, Inc. | Method for treatment of sleep apnea by electrical stimulation |
US5593432A (en) * | 1993-06-23 | 1997-01-14 | Neuroware Therapy International, Inc. | Method for neurostimulation for pain alleviation |
US5601611A (en) * | 1994-08-05 | 1997-02-11 | Ventritex, Inc. | Optical blood flow measurement apparatus and method and implantable defibrillator incorporating same |
US5611350A (en) * | 1996-02-08 | 1997-03-18 | John; Michael S. | Method and apparatus for facilitating recovery of patients in deep coma |
US5618531A (en) * | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
US5707334A (en) * | 1995-08-21 | 1998-01-13 | Young; Robert B. | Method of treating amygdala related transitory disorders |
US5711316A (en) * | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US5713923A (en) * | 1996-05-13 | 1998-02-03 | Medtronic, Inc. | Techniques for treating epilepsy by brain stimulation and drug infusion |
US5713922A (en) * | 1996-04-25 | 1998-02-03 | Medtronic, Inc. | Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain |
US5722401A (en) * | 1994-10-19 | 1998-03-03 | Cardiac Pathways Corporation | Endocardial mapping and/or ablation catheter probe |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US5865842A (en) * | 1996-08-29 | 1999-02-02 | Medtronic, Inc. | System and method for anchoring brain stimulation lead or catheter |
US5871517A (en) * | 1997-01-15 | 1999-02-16 | Somatics, Inc. | Convulsive therapy apparatus to stimulate and monitor the extent of therapeutic value of the treatment |
US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
US5886769A (en) * | 1998-05-18 | 1999-03-23 | Zolten; A. J. | Method of training and rehabilitating brain function using hemi-lenses |
US5896883A (en) * | 1996-01-31 | 1999-04-27 | Khalatbari; Bijan | Portable liquid mud plant |
US6011996A (en) * | 1998-01-20 | 2000-01-04 | Medtronic, Inc | Dual electrode lead and method for brain target localization in functional stereotactic brain surgery |
US6016449A (en) * | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6018682A (en) * | 1998-04-30 | 2000-01-25 | Medtronic, Inc. | Implantable seizure warning system |
US6021352A (en) * | 1996-06-26 | 2000-02-01 | Medtronic, Inc, | Diagnostic testing methods and apparatus for implantable therapy devices |
US6026326A (en) * | 1997-01-13 | 2000-02-15 | Medtronic, Inc. | Apparatus and method for treating chronic constipation |
US6035236A (en) * | 1998-07-13 | 2000-03-07 | Bionergy Therapeutics, Inc. | Methods and apparatus for electrical microcurrent stimulation therapy |
US6038480A (en) * | 1996-04-04 | 2000-03-14 | Medtronic, Inc. | Living tissue stimulation and recording techniques with local control of active sites |
US6040180A (en) * | 1996-05-23 | 2000-03-21 | Neuralstem Biopharmaceuticals, Ltd. | In vitro generation of differentiated neurons from cultures of mammalian multipotential CNS stem cells |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6052624A (en) * | 1999-01-07 | 2000-04-18 | Advanced Bionics Corporation | Directional programming for implantable electrode arrays |
US6055456A (en) * | 1999-04-29 | 2000-04-25 | Medtronic, Inc. | Single and multi-polar implantable lead for sacral nerve electrical stimulation |
US6176242B1 (en) * | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
US6190893B1 (en) * | 1998-09-18 | 2001-02-20 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of bone marrow stromal cells |
US6198958B1 (en) * | 1998-06-11 | 2001-03-06 | Beth Israel Deaconess Medical Center, Inc. | Method and apparatus for monitoring a magnetic resonance image during transcranial magnetic stimulation |
US6205361B1 (en) * | 1998-02-10 | 2001-03-20 | Advanced Bionics Corporation | Implantable expandable multicontact electrodes |
US6205360B1 (en) * | 1995-09-07 | 2001-03-20 | Cochlear Limited | Apparatus and method for automatically determining stimulation parameters |
US6210417B1 (en) * | 1999-04-29 | 2001-04-03 | Medtronic, Inc. | Medical lead positioning and anchoring system |
US6339725B1 (en) * | 1996-05-31 | 2002-01-15 | The Board Of Trustees Of Southern Illinois University | Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation |
US6353762B1 (en) * | 1999-04-30 | 2002-03-05 | Medtronic, Inc. | Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve |
US6353754B1 (en) * | 2000-04-24 | 2002-03-05 | Neuropace, Inc. | System for the creation of patient specific templates for epileptiform activity detection |
US6356786B1 (en) * | 2000-01-20 | 2002-03-12 | Electrocore Techniques, Llc | Method of treating palmar hyperhydrosis by electrical stimulation of the sympathetic nervous chain |
US6356792B1 (en) * | 2000-01-20 | 2002-03-12 | Electro Core Technologies, Llc | Skull mounted electrode lead securing assembly |
US6354299B1 (en) * | 1997-10-27 | 2002-03-12 | Neuropace, Inc. | Implantable device for patient communication |
US6505075B1 (en) * | 1999-05-29 | 2003-01-07 | Richard L. Weiner | Peripheral nerve stimulation method |
US6507755B1 (en) * | 1998-12-01 | 2003-01-14 | Neurometrix, Inc. | Apparatus and method for stimulating human tissue |
US20030028072A1 (en) * | 2000-08-31 | 2003-02-06 | Neuropace, Inc. | Low frequency magnetic neurostimulator for the treatment of neurological disorders |
US6529774B1 (en) * | 2000-11-09 | 2003-03-04 | Neuropace, Inc. | Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation |
US6539263B1 (en) * | 1999-06-11 | 2003-03-25 | Cornell Research Foundation, Inc. | Feedback mechanism for deep brain stimulation |
US6684105B2 (en) * | 2001-08-31 | 2004-01-27 | Biocontrol Medical, Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US6687525B2 (en) * | 2000-06-07 | 2004-02-03 | New York University | Method and system for diagnosing and treating thalamocortical dysrhythmia |
US6690974B2 (en) * | 2000-04-05 | 2004-02-10 | Neuropace, Inc. | Stimulation signal generator for an implantable device |
US6708064B2 (en) * | 2000-02-24 | 2004-03-16 | Ali R. Rezai | Modulation of the brain to affect psychiatric disorders |
US6839594B2 (en) * | 2001-04-26 | 2005-01-04 | Biocontrol Medical Ltd | Actuation and control of limbs through motor nerve stimulation |
US20050004620A1 (en) * | 2002-12-09 | 2005-01-06 | Medtronic, Inc. | Implantable medical device with anti-infection agent |
US20050013310A1 (en) * | 1998-04-20 | 2005-01-20 | Broadcom Corporation | Apparatus and method for unilateral topology discovery in network management |
US20050015129A1 (en) * | 1999-12-09 | 2005-01-20 | Mische Hans A. | Methods and devices for the treatment of neurological and physiological disorders |
US20050021105A1 (en) * | 2000-07-13 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a change in a neural-function of a patient |
US20050021106A1 (en) * | 2000-07-13 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US20050021118A1 (en) * | 2000-07-13 | 2005-01-27 | Chris Genau | Apparatuses and systems for applying electrical stimulation to a patient |
US20050021104A1 (en) * | 1998-08-05 | 2005-01-27 | Dilorenzo Daniel John | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US20050021107A1 (en) * | 2001-03-08 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US6850802B2 (en) * | 1998-04-30 | 2005-02-01 | Medtronic, Inc. | Selective brain stimulation using conditioning pulses |
US20050027284A1 (en) * | 2003-06-19 | 2005-02-03 | Advanced Neuromodulation Systems, Inc. | Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
US20050033378A1 (en) * | 2002-12-09 | 2005-02-10 | Sheffield Warren Douglas | Methods for treating and/or collecting information regarding neurological disorders, including language disorders |
US6873872B2 (en) * | 1999-12-07 | 2005-03-29 | George Mason University | Adaptive electric field modulation of neural systems |
US20050070971A1 (en) * | 2003-08-01 | 2005-03-31 | Brad Fowler | Apparatus and methods for applying neural stimulation to a patient |
US20060004422A1 (en) * | 2004-03-11 | 2006-01-05 | Dirk De Ridder | Electrical stimulation system and method for stimulating tissue in the brain to treat a neurological condition |
US20060004423A1 (en) * | 2002-05-09 | 2006-01-05 | Boveja Birinder R | Methods and systems to provide therapy or alleviate symptoms of chronic headache, transformed migraine, and occipital neuralgia by providing rectangular and/or complex electrical pulses to occipital nerves |
US20060015153A1 (en) * | 2004-07-15 | 2006-01-19 | Gliner Bradford E | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
US6990377B2 (en) * | 2003-04-24 | 2006-01-24 | Northstar Neuroscience, Inc. | Systems and methods for facilitating and/or effectuating development, rehabilitation, restoration, and/or recovery of visual function through neural stimulation |
US20060020297A1 (en) * | 2004-07-20 | 2006-01-26 | Gerber Martin T | Neurostimulation system with distributed stimulators |
US7006859B1 (en) * | 2002-07-20 | 2006-02-28 | Flint Hills Scientific, L.L.C. | Unitized electrode with three-dimensional multi-site, multi-modal capabilities for detection and control of brain state changes |
US7010351B2 (en) * | 2000-07-13 | 2006-03-07 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7015816B2 (en) * | 1999-10-29 | 2006-03-21 | Hill-Rom Services, Inc. | Hygiene monitoring system |
US20070032834A1 (en) * | 2000-07-13 | 2007-02-08 | Northstar Neuroscience, Inc. | Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators |
US7184840B2 (en) * | 2002-04-22 | 2007-02-27 | Medtronic, Inc. | Implantable lead with isolated contact coupling |
US7187968B2 (en) * | 2003-10-23 | 2007-03-06 | Duke University | Apparatus for acquiring and transmitting neural signals and related methods |
US7187977B2 (en) * | 2002-06-13 | 2007-03-06 | Atlantic Medical, Inc. | Transcutaneous electrical nerve stimulation device and method using microcurrent |
US20070055320A1 (en) * | 2005-09-07 | 2007-03-08 | Northstar Neuroscience, Inc. | Methods for treating temporal lobe epilepsy, associated neurological disorders, and other patient functions |
US7191018B2 (en) * | 1998-04-30 | 2007-03-13 | Medtronic, Inc. | Techniques for positioning therapy delivery elements within a spinal cord or brain |
US20080039895A1 (en) * | 2006-04-11 | 2008-02-14 | Northstar Neuroscience, Inc. | Electromagnetic signal delivery for tissue affected by neuronal dysfunction, degradation, damage, and/or necrosis, and associated systems and methods |
US20080045775A1 (en) * | 2003-12-23 | 2008-02-21 | Andres M Lozano | Method and Apparatus for Affecting Neurologic Function and/or Treating Neurologic Dysfunction Through Timed Neural Stimulation |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4542752A (en) | 1983-04-22 | 1985-09-24 | Cordis Corporation | Implantable device having porous surface with carbon coating |
US4844075A (en) | 1984-01-09 | 1989-07-04 | Pain Suppression Labs, Inc. | Transcranial stimulation for the treatment of cerebral palsy |
US4607639A (en) | 1984-05-18 | 1986-08-26 | Regents Of The University Of California | Method and system for controlling bladder evacuation |
US5054906A (en) | 1986-01-17 | 1991-10-08 | Brimfield Precision, Inc. | Indirectly illuminating ophthalmological speculum |
US4865048A (en) | 1987-12-31 | 1989-09-12 | Eckerson Harold D | Method and apparatus for drug free neurostimulation |
DE3914662A1 (en) | 1989-05-03 | 1990-11-08 | Alt Eckhard | DEVICE FOR TRANSMITTING ELECTRICAL SIGNALS BETWEEN AN IMPLANTABLE MEDICAL DEVICE AND ELECTRICALLY EXPENSIBLE HUMAN TISSUE |
US5031618A (en) | 1990-03-07 | 1991-07-16 | Medtronic, Inc. | Position-responsive neuro stimulator |
US5314458A (en) * | 1990-06-01 | 1994-05-24 | University Of Michigan | Single channel microstimulator |
US5224491A (en) | 1991-01-07 | 1993-07-06 | Medtronic, Inc. | Implantable electrode for location within a blood vessel |
US5215086A (en) | 1991-05-03 | 1993-06-01 | Cyberonics, Inc. | Therapeutic treatment of migraine symptoms by stimulation |
US5255678A (en) | 1991-06-21 | 1993-10-26 | Ecole Polytechnique | Mapping electrode balloon |
US5169384A (en) | 1991-08-16 | 1992-12-08 | Bosniak Stephen L | Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue |
US5263967B1 (en) | 1992-05-15 | 2000-12-19 | Brimfield Prec Inc | Medical instrument with dual action drive |
US5476494A (en) | 1992-09-11 | 1995-12-19 | Massachusetts Institute Of Technology | Low pressure neural contact structure |
US5370672A (en) | 1992-10-30 | 1994-12-06 | The Johns Hopkins University | Computer-controlled neurological stimulation system |
US5358513A (en) | 1992-12-09 | 1994-10-25 | Medtronic, Inc. | Parameter selection and electrode placement of neuromuscular electrical stimulation apparatus |
SE9203734D0 (en) | 1992-12-11 | 1992-12-11 | Siemens Elema Ab | defibrillation |
US5537512A (en) | 1993-05-26 | 1996-07-16 | Northrop Grumman Corporation | Neural network elements |
US5411540A (en) | 1993-06-03 | 1995-05-02 | Massachusetts Institute Of Technology | Method and apparatus for preferential neuron stimulation |
US5540736A (en) | 1993-08-02 | 1996-07-30 | Haimovich; Yechiel | Transcranial electrostimulation apparatus having two electrode pairs and independent current generators |
US5417719A (en) | 1993-08-25 | 1995-05-23 | Medtronic, Inc. | Method of using a spinal cord stimulation lead |
US6152143A (en) | 1994-05-09 | 2000-11-28 | Somnus Medical Technologies, Inc. | Method for treatment of air way obstructions |
US5549655A (en) | 1994-09-21 | 1996-08-27 | Medtronic, Inc. | Method and apparatus for synchronized treatment of obstructive sleep apnea |
US6480743B1 (en) | 2000-04-05 | 2002-11-12 | Neuropace, Inc. | System and method for adaptive brain stimulation |
US6463328B1 (en) * | 1996-02-02 | 2002-10-08 | Michael Sasha John | Adaptive brain stimulation method and system |
US6066163A (en) | 1996-02-02 | 2000-05-23 | John; Michael Sasha | Adaptive brain stimulation method and system |
US6126657A (en) | 1996-02-23 | 2000-10-03 | Somnus Medical Technologies, Inc. | Apparatus for treatment of air way obstructions |
US5904916A (en) | 1996-03-05 | 1999-05-18 | Hirsch; Alan R. | Use of odorants to alter learning capacity |
EP0796634B1 (en) | 1996-03-21 | 2005-11-16 | BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin | Implantable stimulation electrode |
US5702429A (en) | 1996-04-04 | 1997-12-30 | Medtronic, Inc. | Neural stimulation techniques with feedback |
US5628317A (en) | 1996-04-04 | 1997-05-13 | Medtronic, Inc. | Ultrasonic techniques for neurostimulator control |
US5925070A (en) | 1996-04-04 | 1999-07-20 | Medtronic, Inc. | Techniques for adjusting the locus of excitation of electrically excitable tissue |
US5824021A (en) | 1996-04-25 | 1998-10-20 | Medtronic Inc. | Method and apparatus for providing feedback to spinal cord stimulation for angina |
US5683422A (en) | 1996-04-25 | 1997-11-04 | Medtronic, Inc. | Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation |
US5716377A (en) | 1996-04-25 | 1998-02-10 | Medtronic, Inc. | Method of treating movement disorders by brain stimulation |
US5782798A (en) | 1996-06-26 | 1998-07-21 | Medtronic, Inc. | Techniques for treating eating disorders by brain stimulation and drug infusion |
US5797970A (en) | 1996-09-04 | 1998-08-25 | Medtronic, Inc. | System, adaptor and method to provide medical electrical stimulation |
US5843148A (en) | 1996-09-27 | 1998-12-01 | Medtronic, Inc. | High resolution brain stimulation lead and method of use |
US5752979A (en) | 1996-11-01 | 1998-05-19 | Medtronic, Inc. | Method of controlling epilepsy by brain stimulation |
US6057847A (en) | 1996-12-20 | 2000-05-02 | Jenkins; Barry | System and method of image generation and encoding using primitive reprojection |
US5948007A (en) | 1997-04-30 | 1999-09-07 | Medtronic, Inc. | Dual channel implantation neurostimulation techniques |
US5893883A (en) | 1997-04-30 | 1999-04-13 | Medtronic, Inc. | Portable stimulation screening device for screening therapeutic effect of electrical stimulation on a patient user during normal activities of the patient user |
US5975085A (en) | 1997-05-01 | 1999-11-02 | Medtronic, Inc. | Method of treating schizophrenia by brain stimulation and drug infusion |
US6128537A (en) | 1997-05-01 | 2000-10-03 | Medtronic, Inc | Techniques for treating anxiety by brain stimulation and drug infusion |
US5861017A (en) | 1997-06-06 | 1999-01-19 | Shriners Hospitals For Children | Portable functional electrical stimulation (FES) system for upper or lower extremity applications |
US5843150A (en) | 1997-10-08 | 1998-12-01 | Medtronic, Inc. | System and method for providing electrical and/or fluid treatment within a patient's brain |
US5941906A (en) | 1997-10-15 | 1999-08-24 | Medtronic, Inc. | Implantable, modular tissue stimulator |
US5938688A (en) | 1997-10-22 | 1999-08-17 | Cornell Research Foundation, Inc. | Deep brain stimulation method |
US6427086B1 (en) | 1997-10-27 | 2002-07-30 | Neuropace, Inc. | Means and method for the intracranial placement of a neurostimulator |
US6459936B2 (en) | 1997-10-27 | 2002-10-01 | Neuropace, Inc. | Methods for responsively treating neurological disorders |
US6221908B1 (en) * | 1998-03-12 | 2001-04-24 | Scientific Learning Corporation | System for stimulating brain plasticity |
US6058331A (en) | 1998-04-27 | 2000-05-02 | Medtronic, Inc. | Apparatus and method for treating peripheral vascular disease and organ ischemia by electrical stimulation with closed loop feedback control |
US5938689A (en) | 1998-05-01 | 1999-08-17 | Neuropace, Inc. | Electrode configuration for a brain neuropacemaker |
US6006124A (en) | 1998-05-01 | 1999-12-21 | Neuropace, Inc. | Means and method for the placement of brain electrodes |
US6104960A (en) | 1998-07-13 | 2000-08-15 | Medtronic, Inc. | System and method for providing medical electrical stimulation to a portion of the nervous system |
US6366813B1 (en) * | 1998-08-05 | 2002-04-02 | Dilorenzo Daniel J. | Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease |
US6253109B1 (en) * | 1998-11-05 | 2001-06-26 | Medtronic Inc. | System for optimized brain stimulation |
US6161044A (en) * | 1998-11-23 | 2000-12-12 | Synaptic Corporation | Method and apparatus for treating chronic pain syndromes, tremor, dementia and related disorders and for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation |
US6161045A (en) | 1999-06-01 | 2000-12-12 | Neuropace, Inc. | Method for determining stimulation parameters for the treatment of epileptic seizures |
US6499488B1 (en) * | 1999-10-28 | 2002-12-31 | Winchester Development Associates | Surgical sensor |
TW483768B (en) * | 1999-12-07 | 2002-04-21 | George Mason Universityi | Adaptive electric field modulation of neural systems |
US6418344B1 (en) * | 2000-02-24 | 2002-07-09 | Electrocore Techniques, Llc | Method of treating psychiatric disorders by electrical stimulation within the orbitofrontal cerebral cortex |
US6473639B1 (en) | 2000-03-02 | 2002-10-29 | Neuropace, Inc. | Neurological event detection procedure using processed display channel based algorithms and devices incorporating these procedures |
US6405079B1 (en) * | 2000-09-22 | 2002-06-11 | Mehdi M. Ansarinia | Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions |
US7110820B2 (en) * | 2002-02-05 | 2006-09-19 | Tcheng Thomas K | Responsive electrical stimulation for movement disorders |
-
2003
- 2003-07-17 US US10/622,898 patent/US6959215B2/en not_active Expired - Fee Related
- 2003-12-09 WO PCT/US2003/039078 patent/WO2004058347A1/en not_active Application Discontinuation
- 2003-12-09 AU AU2003297762A patent/AU2003297762A1/en not_active Abandoned
-
2005
- 2005-10-11 US US11/249,034 patent/US20060217780A1/en not_active Abandoned
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3024702A (en) * | 1959-04-27 | 1962-03-13 | Reinholdt Friedrich | Emergency warning device |
US3650276A (en) * | 1969-03-26 | 1972-03-21 | Inst Demedicina Si Farmacie | Method and apparatus, including a flexible electrode, for the electric neurostimulation of the neurogenic bladder |
US4019518A (en) * | 1975-08-11 | 1977-04-26 | Medtronic, Inc. | Electrical stimulation system |
US4140133A (en) * | 1977-04-26 | 1979-02-20 | Moskovsky Oblastnoi Nauchno-Issledovatelsky Institut Akusherstva I Ginekolog Ii | Device for pulse current action on central nervous system |
US4245645A (en) * | 1977-09-28 | 1981-01-20 | Arseneault Pierre Michel | Self-locking cerebral electrical probe |
US4431000A (en) * | 1978-11-29 | 1984-02-14 | Gatron Corporation | Transcutaneous nerve stimulator with pseusorandom pulse generator |
US4308868A (en) * | 1980-05-27 | 1982-01-05 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Implantable electrical device |
US4646744A (en) * | 1984-06-29 | 1987-03-03 | Zion Foundation | Method and treatment with transcranially applied electrical signals |
US4817634A (en) * | 1987-06-18 | 1989-04-04 | Medtronic, Inc. | Epicardial patch electrode |
US4903702A (en) * | 1988-10-17 | 1990-02-27 | Ad-Tech Medical Instrument Corporation | Brain-contact for sensing epileptogenic foci with improved accuracy |
US5002053A (en) * | 1989-04-21 | 1991-03-26 | University Of Arkansas | Method of and device for inducing locomotion by electrical stimulation of the spinal cord |
US5282468A (en) * | 1990-06-07 | 1994-02-01 | Medtronic, Inc. | Implantable neural electrode |
US5092835A (en) * | 1990-07-06 | 1992-03-03 | Schurig Janet L S | Brain and nerve healing power apparatus and method |
US5618531A (en) * | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
US5299569A (en) * | 1991-05-03 | 1994-04-05 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by nerve stimulation |
US5304206A (en) * | 1991-11-18 | 1994-04-19 | Cyberonics, Inc. | Activation techniques for implantable medical device |
US5193540A (en) * | 1991-12-18 | 1993-03-16 | Alfred E. Mann Foundation For Scientific Research | Structure and method of manufacture of an implantable microstimulator |
US5184620A (en) * | 1991-12-26 | 1993-02-09 | Marquette Electronics, Inc. | Method of using a multiple electrode pad assembly |
US5406957A (en) * | 1992-02-05 | 1995-04-18 | Tansey; Michael A. | Electroencephalic neurofeedback apparatus for training and tracking of cognitive states |
US5303705A (en) * | 1992-05-01 | 1994-04-19 | Nenov Valeriy I | Evoked 23NA MR imaging of sodium currents in the brain |
US5593432A (en) * | 1993-06-23 | 1997-01-14 | Neuroware Therapy International, Inc. | Method for neurostimulation for pain alleviation |
US5405375A (en) * | 1994-01-21 | 1995-04-11 | Incontrol, Inc. | Combined mapping, pacing, and defibrillating catheter |
US5601611A (en) * | 1994-08-05 | 1997-02-11 | Ventritex, Inc. | Optical blood flow measurement apparatus and method and implantable defibrillator incorporating same |
US5722401A (en) * | 1994-10-19 | 1998-03-03 | Cardiac Pathways Corporation | Endocardial mapping and/or ablation catheter probe |
US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
US5591216A (en) * | 1995-05-19 | 1997-01-07 | Medtronic, Inc. | Method for treatment of sleep apnea by electrical stimulation |
US5707334A (en) * | 1995-08-21 | 1998-01-13 | Young; Robert B. | Method of treating amygdala related transitory disorders |
US6205360B1 (en) * | 1995-09-07 | 2001-03-20 | Cochlear Limited | Apparatus and method for automatically determining stimulation parameters |
US5896883A (en) * | 1996-01-31 | 1999-04-27 | Khalatbari; Bijan | Portable liquid mud plant |
US5611350A (en) * | 1996-02-08 | 1997-03-18 | John; Michael S. | Method and apparatus for facilitating recovery of patients in deep coma |
US6038480A (en) * | 1996-04-04 | 2000-03-14 | Medtronic, Inc. | Living tissue stimulation and recording techniques with local control of active sites |
US5713922A (en) * | 1996-04-25 | 1998-02-03 | Medtronic, Inc. | Techniques for adjusting the locus of excitation of neural tissue in the spinal cord or brain |
US5711316A (en) * | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US5713923A (en) * | 1996-05-13 | 1998-02-03 | Medtronic, Inc. | Techniques for treating epilepsy by brain stimulation and drug infusion |
US6040180A (en) * | 1996-05-23 | 2000-03-21 | Neuralstem Biopharmaceuticals, Ltd. | In vitro generation of differentiated neurons from cultures of mammalian multipotential CNS stem cells |
US6339725B1 (en) * | 1996-05-31 | 2002-01-15 | The Board Of Trustees Of Southern Illinois University | Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation |
US6021352A (en) * | 1996-06-26 | 2000-02-01 | Medtronic, Inc, | Diagnostic testing methods and apparatus for implantable therapy devices |
US5865842A (en) * | 1996-08-29 | 1999-02-02 | Medtronic, Inc. | System and method for anchoring brain stimulation lead or catheter |
US6026326A (en) * | 1997-01-13 | 2000-02-15 | Medtronic, Inc. | Apparatus and method for treating chronic constipation |
US5871517A (en) * | 1997-01-15 | 1999-02-16 | Somatics, Inc. | Convulsive therapy apparatus to stimulate and monitor the extent of therapeutic value of the treatment |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6360122B1 (en) * | 1997-10-27 | 2002-03-19 | Neuropace, Inc. | Data recording methods for an implantable device |
US6016449A (en) * | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6354299B1 (en) * | 1997-10-27 | 2002-03-12 | Neuropace, Inc. | Implantable device for patient communication |
US6011996A (en) * | 1998-01-20 | 2000-01-04 | Medtronic, Inc | Dual electrode lead and method for brain target localization in functional stereotactic brain surgery |
US6205361B1 (en) * | 1998-02-10 | 2001-03-20 | Advanced Bionics Corporation | Implantable expandable multicontact electrodes |
US20050013310A1 (en) * | 1998-04-20 | 2005-01-20 | Broadcom Corporation | Apparatus and method for unilateral topology discovery in network management |
US7191018B2 (en) * | 1998-04-30 | 2007-03-13 | Medtronic, Inc. | Techniques for positioning therapy delivery elements within a spinal cord or brain |
US6850802B2 (en) * | 1998-04-30 | 2005-02-01 | Medtronic, Inc. | Selective brain stimulation using conditioning pulses |
US6018682A (en) * | 1998-04-30 | 2000-01-25 | Medtronic, Inc. | Implantable seizure warning system |
US5886769A (en) * | 1998-05-18 | 1999-03-23 | Zolten; A. J. | Method of training and rehabilitating brain function using hemi-lenses |
US6198958B1 (en) * | 1998-06-11 | 2001-03-06 | Beth Israel Deaconess Medical Center, Inc. | Method and apparatus for monitoring a magnetic resonance image during transcranial magnetic stimulation |
US6035236A (en) * | 1998-07-13 | 2000-03-07 | Bionergy Therapeutics, Inc. | Methods and apparatus for electrical microcurrent stimulation therapy |
US20050021104A1 (en) * | 1998-08-05 | 2005-01-27 | Dilorenzo Daniel John | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US6190893B1 (en) * | 1998-09-18 | 2001-02-20 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of bone marrow stromal cells |
US6507755B1 (en) * | 1998-12-01 | 2003-01-14 | Neurometrix, Inc. | Apparatus and method for stimulating human tissue |
US6052624A (en) * | 1999-01-07 | 2000-04-18 | Advanced Bionics Corporation | Directional programming for implantable electrode arrays |
US6055456A (en) * | 1999-04-29 | 2000-04-25 | Medtronic, Inc. | Single and multi-polar implantable lead for sacral nerve electrical stimulation |
US6210417B1 (en) * | 1999-04-29 | 2001-04-03 | Medtronic, Inc. | Medical lead positioning and anchoring system |
US6176242B1 (en) * | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
US6353762B1 (en) * | 1999-04-30 | 2002-03-05 | Medtronic, Inc. | Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve |
US6505075B1 (en) * | 1999-05-29 | 2003-01-07 | Richard L. Weiner | Peripheral nerve stimulation method |
US6539263B1 (en) * | 1999-06-11 | 2003-03-25 | Cornell Research Foundation, Inc. | Feedback mechanism for deep brain stimulation |
US7015816B2 (en) * | 1999-10-29 | 2006-03-21 | Hill-Rom Services, Inc. | Hygiene monitoring system |
US6873872B2 (en) * | 1999-12-07 | 2005-03-29 | George Mason University | Adaptive electric field modulation of neural systems |
US20050015129A1 (en) * | 1999-12-09 | 2005-01-20 | Mische Hans A. | Methods and devices for the treatment of neurological and physiological disorders |
US6356786B1 (en) * | 2000-01-20 | 2002-03-12 | Electrocore Techniques, Llc | Method of treating palmar hyperhydrosis by electrical stimulation of the sympathetic nervous chain |
US6356792B1 (en) * | 2000-01-20 | 2002-03-12 | Electro Core Technologies, Llc | Skull mounted electrode lead securing assembly |
US6708064B2 (en) * | 2000-02-24 | 2004-03-16 | Ali R. Rezai | Modulation of the brain to affect psychiatric disorders |
US6690974B2 (en) * | 2000-04-05 | 2004-02-10 | Neuropace, Inc. | Stimulation signal generator for an implantable device |
US6353754B1 (en) * | 2000-04-24 | 2002-03-05 | Neuropace, Inc. | System for the creation of patient specific templates for epileptiform activity detection |
US6687525B2 (en) * | 2000-06-07 | 2004-02-03 | New York University | Method and system for diagnosing and treating thalamocortical dysrhythmia |
US20050021106A1 (en) * | 2000-07-13 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US20050021118A1 (en) * | 2000-07-13 | 2005-01-27 | Chris Genau | Apparatuses and systems for applying electrical stimulation to a patient |
US7010351B2 (en) * | 2000-07-13 | 2006-03-07 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US20050021105A1 (en) * | 2000-07-13 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a change in a neural-function of a patient |
US20070032834A1 (en) * | 2000-07-13 | 2007-02-08 | Northstar Neuroscience, Inc. | Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators |
US20030028072A1 (en) * | 2000-08-31 | 2003-02-06 | Neuropace, Inc. | Low frequency magnetic neurostimulator for the treatment of neurological disorders |
US6529774B1 (en) * | 2000-11-09 | 2003-03-04 | Neuropace, Inc. | Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation |
US20050021107A1 (en) * | 2001-03-08 | 2005-01-27 | Firlik Andrew D. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US6839594B2 (en) * | 2001-04-26 | 2005-01-04 | Biocontrol Medical Ltd | Actuation and control of limbs through motor nerve stimulation |
US6684105B2 (en) * | 2001-08-31 | 2004-01-27 | Biocontrol Medical, Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US7184840B2 (en) * | 2002-04-22 | 2007-02-27 | Medtronic, Inc. | Implantable lead with isolated contact coupling |
US20060004423A1 (en) * | 2002-05-09 | 2006-01-05 | Boveja Birinder R | Methods and systems to provide therapy or alleviate symptoms of chronic headache, transformed migraine, and occipital neuralgia by providing rectangular and/or complex electrical pulses to occipital nerves |
US7187977B2 (en) * | 2002-06-13 | 2007-03-06 | Atlantic Medical, Inc. | Transcutaneous electrical nerve stimulation device and method using microcurrent |
US7006859B1 (en) * | 2002-07-20 | 2006-02-28 | Flint Hills Scientific, L.L.C. | Unitized electrode with three-dimensional multi-site, multi-modal capabilities for detection and control of brain state changes |
US20050033378A1 (en) * | 2002-12-09 | 2005-02-10 | Sheffield Warren Douglas | Methods for treating and/or collecting information regarding neurological disorders, including language disorders |
US20050004620A1 (en) * | 2002-12-09 | 2005-01-06 | Medtronic, Inc. | Implantable medical device with anti-infection agent |
US6990377B2 (en) * | 2003-04-24 | 2006-01-24 | Northstar Neuroscience, Inc. | Systems and methods for facilitating and/or effectuating development, rehabilitation, restoration, and/or recovery of visual function through neural stimulation |
US20050027284A1 (en) * | 2003-06-19 | 2005-02-03 | Advanced Neuromodulation Systems, Inc. | Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
US20050070971A1 (en) * | 2003-08-01 | 2005-03-31 | Brad Fowler | Apparatus and methods for applying neural stimulation to a patient |
US7187968B2 (en) * | 2003-10-23 | 2007-03-06 | Duke University | Apparatus for acquiring and transmitting neural signals and related methods |
US20080045775A1 (en) * | 2003-12-23 | 2008-02-21 | Andres M Lozano | Method and Apparatus for Affecting Neurologic Function and/or Treating Neurologic Dysfunction Through Timed Neural Stimulation |
US20060004422A1 (en) * | 2004-03-11 | 2006-01-05 | Dirk De Ridder | Electrical stimulation system and method for stimulating tissue in the brain to treat a neurological condition |
US20060015153A1 (en) * | 2004-07-15 | 2006-01-19 | Gliner Bradford E | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
US20060020297A1 (en) * | 2004-07-20 | 2006-01-26 | Gerber Martin T | Neurostimulation system with distributed stimulators |
US20070055320A1 (en) * | 2005-09-07 | 2007-03-08 | Northstar Neuroscience, Inc. | Methods for treating temporal lobe epilepsy, associated neurological disorders, and other patient functions |
US20080039895A1 (en) * | 2006-04-11 | 2008-02-14 | Northstar Neuroscience, Inc. | Electromagnetic signal delivery for tissue affected by neuronal dysfunction, degradation, damage, and/or necrosis, and associated systems and methods |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9616234B2 (en) | 2002-05-03 | 2017-04-11 | Trustees Of Boston University | System and method for neuro-stimulation |
US8565867B2 (en) | 2005-01-28 | 2013-10-22 | Cyberonics, Inc. | Changeable electrode polarity stimulation by an implantable medical device |
US9586047B2 (en) | 2005-01-28 | 2017-03-07 | Cyberonics, Inc. | Contingent cardio-protection for epilepsy patients |
US7996079B2 (en) | 2006-01-24 | 2011-08-09 | Cyberonics, Inc. | Input response override for an implantable medical device |
US9289599B2 (en) | 2006-03-29 | 2016-03-22 | Dignity Health | Vagus nerve stimulation method |
US8219188B2 (en) | 2006-03-29 | 2012-07-10 | Catholic Healthcare West | Synchronization of vagus nerve stimulation with the cardiac cycle of a patient |
US8615309B2 (en) | 2006-03-29 | 2013-12-24 | Catholic Healthcare West | Microburst electrical stimulation of cranial nerves for the treatment of medical conditions |
US8738126B2 (en) | 2006-03-29 | 2014-05-27 | Catholic Healthcare West | Synchronization of vagus nerve stimulation with the cardiac cycle of a patient |
US8150508B2 (en) | 2006-03-29 | 2012-04-03 | Catholic Healthcare West | Vagus nerve stimulation method |
US9108041B2 (en) | 2006-03-29 | 2015-08-18 | Dignity Health | Microburst electrical stimulation of cranial nerves for the treatment of medical conditions |
US9533151B2 (en) | 2006-03-29 | 2017-01-03 | Dignity Health | Microburst electrical stimulation of cranial nerves for the treatment of medical conditions |
US8280505B2 (en) | 2006-03-29 | 2012-10-02 | Catholic Healthcare West | Vagus nerve stimulation method |
US8660666B2 (en) | 2006-03-29 | 2014-02-25 | Catholic Healthcare West | Microburst electrical stimulation of cranial nerves for the treatment of medical conditions |
US7869885B2 (en) | 2006-04-28 | 2011-01-11 | Cyberonics, Inc | Threshold optimization for tissue stimulation therapy |
US7962220B2 (en) | 2006-04-28 | 2011-06-14 | Cyberonics, Inc. | Compensation reduction in tissue stimulation therapy |
US7869867B2 (en) | 2006-10-27 | 2011-01-11 | Cyberonics, Inc. | Implantable neurostimulator with refractory stimulation |
US7962214B2 (en) | 2007-04-26 | 2011-06-14 | Cyberonics, Inc. | Non-surgical device and methods for trans-esophageal vagus nerve stimulation |
US7869884B2 (en) | 2007-04-26 | 2011-01-11 | Cyberonics, Inc. | Non-surgical device and methods for trans-esophageal vagus nerve stimulation |
US7904175B2 (en) | 2007-04-26 | 2011-03-08 | Cyberonics, Inc. | Trans-esophageal vagus nerve stimulation |
US8306627B2 (en) | 2007-04-27 | 2012-11-06 | Cyberonics, Inc. | Dosing limitation for an implantable medical device |
US7974701B2 (en) | 2007-04-27 | 2011-07-05 | Cyberonics, Inc. | Dosing limitation for an implantable medical device |
US8260426B2 (en) | 2008-01-25 | 2012-09-04 | Cyberonics, Inc. | Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device |
US9314633B2 (en) | 2008-01-25 | 2016-04-19 | Cyberonics, Inc. | Contingent cardio-protection for epilepsy patients |
US8204603B2 (en) | 2008-04-25 | 2012-06-19 | Cyberonics, Inc. | Blocking exogenous action potentials by an implantable medical device |
US8874218B2 (en) | 2008-10-20 | 2014-10-28 | Cyberonics, Inc. | Neurostimulation with signal duration determined by a cardiac cycle |
US8457747B2 (en) | 2008-10-20 | 2013-06-04 | Cyberonics, Inc. | Neurostimulation with signal duration determined by a cardiac cycle |
US10653883B2 (en) | 2009-01-23 | 2020-05-19 | Livanova Usa, Inc. | Implantable medical device for providing chronic condition therapy and acute condition therapy using vagus nerve stimulation |
US8600513B2 (en) * | 2010-12-09 | 2013-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Seizure prediction and neurological disorder treatment |
US20120150257A1 (en) * | 2010-12-09 | 2012-06-14 | Dorian Aur | Seizure prediction and neurological disorder treatment |
CN108211110A (en) * | 2013-01-21 | 2018-06-29 | 卡拉健康公司 | For controlling the device and method trembled |
Also Published As
Publication number | Publication date |
---|---|
WO2004058347A1 (en) | 2004-07-15 |
US20040111129A1 (en) | 2004-06-10 |
AU2003297762A1 (en) | 2004-07-22 |
US6959215B2 (en) | 2005-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6959215B2 (en) | Methods for treating essential tremor | |
US7299096B2 (en) | System and method for treating Parkinson's Disease and other movement disorders | |
US20240342483A1 (en) | Brain stimulation system including diagnostic tool | |
US7437196B2 (en) | Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects | |
US8126562B2 (en) | Apparatus and methods for applying neural stimulation to a patient | |
US8050767B2 (en) | Methods for treating and/or collecting information regarding neurological disorders, including language disorders | |
US20080033503A1 (en) | Electrode configurations for reducing invasiveness and/or enhancing neural stimulation efficacy, and associated methods | |
US20050075679A1 (en) | Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system | |
US20040153129A1 (en) | System and method for controlling neurological disorders with spatially separated detection and therapy locations | |
WO2003055556A1 (en) | Modulation of the brain to affect psychiatric disorders | |
Shivdasani et al. | Visual cortex responses to single-and simultaneous multiple-electrode stimulation of the retina: implications for retinal prostheses | |
WO2004052448A1 (en) | System and method for treating parkinson's disease and other movement disorders | |
US7774068B1 (en) | System and method for treating movement disorders, including restless leg syndrome | |
Velasco et al. | Interfering with the genesis and propagation of epileptic seizures by neuromodulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADVANCED NEUROMODULATION SYSTEMS, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NORTHSTAR NEUROSCIENCE, INC.;REEL/FRAME:022813/0542 Effective date: 20090521 Owner name: ADVANCED NEUROMODULATION SYSTEMS, INC.,TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NORTHSTAR NEUROSCIENCE, INC.;REEL/FRAME:022813/0542 Effective date: 20090521 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |